# PepLab.wiki — Complete Clinical Reconstitution, Multi-Peptide Blend & Pharmacokinetic Corpus (/llms-full.txt) > Deterministic reference dataset covering all 25 research peptides and multi-compound blends, 58 vial-size dilution setups, U-100/U-40 syringe conversions, first-order pharmacokinetic half-life parameters, and primary literature citations. ## Analytical Reference Guides Hub (/guides) - **Guides Hub URL:** https://peplab.wiki/guides - **Guide 1 — How to Read a Peptide COA:** https://peplab.wiki/guides/how-to-read-peptide-coa - **Guide 2 — Gross Lyophilized Powder Weight vs. Net Peptide Content (Counter-Ions, Moisture, Excipients & C = m / V):** https://peplab.wiki/guides/peptide-net-content-counter-ion-moisture-dilution-guide - **Guide 3 — Document-Led Peptide COA Audit (Dual-Metric vs. Purity-Only & Sample-Size Mismatch Certificates Across 17 Single-Compound Entries):** https://peplab.wiki/guides/dual-metric-vs-purity-only-peptide-coa-audit - **Guide 4 — Multi-Peptide Blend COA Verification & Labeled Mass-Ratio Guide (GLOW 70mg, KLOW 80mg, Wolverine 20mg 10/10 & CJC-1295 / Ipamorelin 10mg 5/5; Full-Length Thymosin Beta-4 [43-mer, CAS 77591-33-4, ~4963.5 Da] vs. Synthetic TB-500 Fragment [Ac-LKKTETQ, 7-mer, ~889.0 Da]):** https://peplab.wiki/guides/multi-peptide-blend-coa-verification-mass-ratio-guide - **Head-to-Head Supplier COA & Catalog Comparison (Simms Research vs. True Peptides):** https://peplab.wiki/compare/simms-research-vs-true-peptides - **Full Multi-Supplier COA & Price Directory:** https://peplab.wiki/research-supplier-comparison - **Core Distinction (ICH Q2(R2), Table 1 & Section 3.1.2.2):** Table 1 distinguishes Impurity (Purity) from Assay (Content/Potency), while Section 3.1.2.2 addresses specificity/selectivity for assay, purity and impurity procedures. Chromatographic purity (% relative peak area on RP-HPLC at 214/220 nm, a laboratory/vendor convention) measures peptide-related UV species and does not quantify moisture, counter-ions (TFA/acetate), or inorganic salts. Quantitative assay (net peptide content) measures actual peptide mass (mg/vial) or concentration (mg/mL) in the tested sample. - **Worked Documented COA Audits (Retatrutide 10 mg):** - Simms Research Lot #2026-G460 (Kovera report, tested 2026-07-16): 99.611% batch-average RP-HPLC purity; 3 vials tested for net content (10.39 mg, 10.74 mg, 11.19 mg -> arithmetic mean 10.77 mg in table vs. 10.68 mg in top summary banner; discrepancy flagged for issuer clarification). - True Peptides Lot #261006 (tested 2026-10-14): LC-MS identity confirmed + 99.9% RP-HPLC purity; does not report a quantitative net content / mass assay (mg/vial). --- ## Retatrutide (LY3437943 / GLP-3) - **Canonical Calculator URL:** https://peplab.wiki/compounds/retatrutide - **Supported Vial Presets:** 5mg, 10mg (default), 12mg, 15mg, 20mg, 30mg - **Category:** GLP-1 / Metabolic (Triple Agonist (GLP-1R / GIPR / GCGR)) - **CAS Registry Number:** 2381089-83-2 - **Molecular Weight:** 4731.33 g/mol - **Sequence / Structure:** 39 amino acids (C20 fatty diacid acylated) - **Pharmacokinetic Evidence Status:** 6 days (144 hours) | Recommended Interval: every 7 days - **Standard Reconstitution (10mg Vial + 2mL BAC Water):** Concentration = 5 mg/mL (50 mcg/unit). Initial 2 mg dose = 0.4 mL = **40 Units** on a U-100 syringe (5 doses/vial). - **Supplier $/mg Basis:** $7.56/labeled mg documented (Simms Research, 10mg SKU = $84.00 USD list, $75.60 USD w/ PEPLAB10, checked 2026-11-02; COA: RP-HPLC (99.611% 3-vial avg purity; 3 vials tested for net content: 10.39/10.74/11.19 mg -> 10.77 mg table mean vs. 10.68 mg summary banner) + LC-MS Identity) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (10mg SKU):** $84.00 USD standard list ($8.40/labeled mg; $75.60 USD / $7.56/mg 1st order w/ PEPLAB10) | COA Status: dual_metric_pdf_linked (Kovera Labs Lot #2026-G460, tested 2026-07-16, RP-HPLC purity 99.611%, net mass 10.77 mg/vial) | COA PDF: https://simmsresearch.com/wp-content/uploads/2026/07/coa-glp-3-rt-10mg-lot-2026-g460-kovera-v2.pdf - **True Peptides (10mg SKU):** $89.00 USD standard list ($8.90/labeled mg) | COA Status: purity_only_pdf_linked (Supplier-Published Batch COA Lot #261006, tested 2026-10-14, RP-HPLC purity 99.9%, net mass not reported on certificate) | COA PDF: https://cdn.true-peptides.com/coa/261006.pdf - **Bergdorf Bioscience (10mg SKU):** $109.99 USD standard list ($11.00/labeled mg; $98.99 USD / $9.90/mg 1st order w/ BIO-QTVGWU) | COA Status: dual_metric_pdf_linked (Janoshik Analytical Lot #10 mg sample; batch unknown, tested 2026-05-11, RP-HPLC purity 99.588%, net mass 10.92 mg/vial) | COA PDF: https://bergdorfbio.com/lab-reports/retatrutide-10mg-147356.png - **Clinical / Experimental Summary:** Retatrutide (LY3437943) is an investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. In the Phase 2 NEJM trial (Jastreboff et al., 2023), the 12 mg once-weekly cohort achieved a mean 24.2% body-weight reduction at 48 weeks. - **Titration & Dosing Schedule (10mg + 2mL BAC):** - Weeks 1–4: 2 mg (2000 mcg) -> 40 Units on U-100 (0.400 mL) | Initiation / receptor acclimation phase (once weekly) - Weeks 5–8: 4 mg (4000 mcg) -> 80 Units on U-100 (0.800 mL) | Primary metabolic step-up (once weekly) - Weeks 9–12: 6 mg (6000 mcg) -> 120 Units on U-100 (1.200 mL) | Intermediate titration step (once weekly) - Weeks 13–16: 9 mg (9000 mcg) -> 180 Units on U-100 (1.800 mL) | High-response therapeutic tier (once weekly) - Weeks 17+: 12 mg (12000 mcg) -> 240 Units on U-100 (2.400 mL) | Maximum Phase 3 TRIUMPH maintenance dose - **Primary Literature Citations:** - Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (Jastreboff et al.) — New England Journal of Medicine (2023) · DOI: 10.1056/NEJMoa2301972 (https://www.nejm.org/doi/full/10.1056/NEJMoa2301972) - Discovery and Pharmacology of LY3437943 (Coskun et al.) — Cell Metabolism (2022) · DOI: 10.1016/j.cmet.2022.07.013 (https://doi.org/10.1016/j.cmet.2022.07.013) - TRIUMPH-1 Phase 3 Study of Retatrutide in Participants With Obesity (NCT05929066) — ClinicalTrials.gov · NCT05929066 (https://clinicaltrials.gov/study/NCT05929066) --- ## Tirzepatide (LY3298176 / Dual GIP + GLP-1) - **Canonical Calculator URL:** https://peplab.wiki/compounds/tirzepatide - **Supported Vial Presets:** 5mg, 10mg, 15mg (default), 20mg, 30mg, 60mg - **Category:** GLP-1 / Metabolic (Dual Incretin Agonist (GIPR / GLP-1R)) - **CAS Registry Number:** 2023788-19-2 - **Molecular Weight:** 4813.45 g/mol - **Sequence / Structure:** 39 amino acids (C20 eicosanedioic acid linker) - **Pharmacokinetic Evidence Status:** 5 days (120 hours) | Recommended Interval: every 7 days - **Standard Reconstitution (15mg Vial + 1.5mL BAC Water):** Concentration = 10 mg/mL (100 mcg/unit). Initial 2.5 mg dose = 0.25 mL = **25 Units** on a U-100 syringe (6 doses/vial). - **Supplier $/mg Basis:** $5.85/labeled mg documented (Simms Research, 10mg SKU = $65.00 USD list, $58.50 USD w/ PEPLAB10, checked 2026-11-02) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (10mg SKU):** $65.00 USD standard list ($6.50/labeled mg; $58.50 USD / $5.85/mg 1st order w/ PEPLAB10) | COA Status: sample_size_mismatch_pdf_linked (Lab Lot #2026-TZ295, tested 2026-07-16, net mass not reported on certificate) | COA PDF: https://simmsresearch.com/wp-content/uploads/2026/07/coa-tirzepatide-10mg-lot-2026-tz295-kovera-v2.pdf - **Bergdorf Bioscience (15mg SKU):** $89.99 USD standard list ($6.00/labeled mg; $80.99 USD / $5.40/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** Tirzepatide is a dual GIP and GLP-1 receptor co-agonist with a 5-day (~120-hour) elimination half-life enabling once-weekly subcutaneous dosing across six 2.5 mg escalation steps up to 15 mg. In SURMOUNT-1 (72 weeks), the 15 mg arm achieved a 20.9% mean weight reduction. - **Titration & Dosing Schedule (15mg + 1.5mL BAC):** - Weeks 1–4: 2.5 mg (2500 mcg) -> 25 Units on U-100 (0.250 mL) | Treatment initiation dose (not for glycemic maintenance) - Weeks 5–8: 5 mg (5000 mcg) -> 50 Units on U-100 (0.500 mL) | First maintenance tier (once weekly) - Weeks 9–12: 7.5 mg (7500 mcg) -> 75 Units on U-100 (0.750 mL) | Step-up escalation (+2.5 mg after ≥4 weeks) - Weeks 13–16: 10 mg (10000 mcg) -> 100 Units on U-100 (1.000 mL) | Secondary maintenance tier (once weekly) - Weeks 17–20: 12.5 mg (12500 mcg) -> 125 Units on U-100 (1.250 mL) | Bridge escalation step - Weeks 21+: 15 mg (15000 mcg) -> 150 Units on U-100 (1.500 mL) | Maximum SURMOUNT-1 maintenance ceiling - **Primary Literature Citations:** - Tirzepatide Once Weekly for the Treatment of Obesity — SURMOUNT-1 (Jastreboff et al.) — New England Journal of Medicine (2022) · DOI: 10.1056/NEJMoa2206038 (https://www.nejm.org/doi/full/10.1056/NEJMoa2206038) - LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist (Coskun et al.) — Molecular Metabolism (2018) · PMC6308032 (https://pmc.ncbi.nlm.nih.gov/articles/PMC6308032/) --- ## Semaglutide (GLP-1 Receptor Agonist) - **Canonical Calculator URL:** https://peplab.wiki/compounds/semaglutide - **Supported Vial Presets:** 2mg, 5mg (default), 10mg, 15mg - **Category:** GLP-1 / Metabolic (Selective GLP-1 Receptor Agonist) - **CAS Registry Number:** 910463-68-2 - **Molecular Weight:** 4113.58 g/mol - **Sequence / Structure:** 31 amino acids (94% homology to human GLP-1) - **Pharmacokinetic Evidence Status:** 7 days (168 hours) | Recommended Interval: every 7 days - **Standard Reconstitution (5mg Vial + 2mL BAC Water):** Concentration = 2.5 mg/mL (25 mcg/unit). Initial 0.25 mg dose = 0.1 mL = **10 Units** on a U-100 syringe (20 doses/vial). - **Supplier $/mg Basis:** ~$6.84/mg est. (Simms Research, code PEPLAB10 — illustrative model estimate; verify live price on supplier site) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Clinical / Experimental Summary:** Semaglutide is a selective long-acting GLP-1 receptor agonist with a 7-day (~168-hour) half-life achieved via C18 fatty diacid albumin binding and DPP-4 stabilization at position 8 (Aib). Standard STEP-1 titration begins at 0.25 mg (250 mcg) weekly and scales to 2.4 mg. - **Titration & Dosing Schedule (5mg + 2mL BAC):** - Weeks 1–4: 0.25 mg (250 mcg) -> 10 Units on U-100 (0.100 mL) | 250 mcg GI acclimation phase (once weekly) - Weeks 5–8: 0.5 mg (500 mcg) -> 20 Units on U-100 (0.200 mL) | 500 mcg early metabolic stabilization - Weeks 9–12: 1 mg (1000 mcg) -> 40 Units on U-100 (0.400 mL) | 1.0 mg intermediate tier - Weeks 13–16: 1.7 mg (1700 mcg) -> 68 Units on U-100 (0.680 mL) | 1.7 mg pre-maintenance step - Weeks 17+: 2.4 mg (2400 mcg) -> 96 Units on U-100 (0.960 mL) | 2.4 mg full STEP-1 maintenance dose - **Primary Literature Citations:** - Once-Weekly Semaglutide in Adults with Overweight or Obesity — STEP 1 (Wilding et al.) — New England Journal of Medicine (2021) · DOI: 10.1056/NEJMoa2032183 (https://www.nejm.org/doi/full/10.1056/NEJMoa2032183) - Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide (Lau et al.) — Journal of Medicinal Chemistry (2015) · PMID: 26308095 (https://pubmed.ncbi.nlm.nih.gov/26308095/) --- ## Cagrilintide (AM833 Long-Acting Amylin Analogue) - **Canonical Calculator URL:** https://peplab.wiki/compounds/cagrilintide - **Supported Vial Presets:** 5mg (default), 10mg - **Category:** GLP-1 / Metabolic (Dual Amylin & Calcitonin Receptor Agonist (DACRA)) - **CAS Registry Number:** 1415456-99-3 - **Molecular Weight:** 4409.01 g/mol - **Sequence / Structure:** 37 amino acids (N-terminal C20 fatty diacid) - **Pharmacokinetic Evidence Status:** 7.5 days (180 hours) | Recommended Interval: every 7 days - **Standard Reconstitution (5mg Vial + 2mL BAC Water):** Concentration = 2.5 mg/mL (25 mcg/unit). Initial 0.25 mg dose = 0.1 mL = **10 Units** on a U-100 syringe (20 doses/vial). - **Supplier $/mg Basis:** $21.60/labeled mg documented (Bergdorf Bioscience, 5mg SKU = $119.99 USD list, $107.99 USD w/ BIO-QTVGWU, checked 2026-11-06) | Verifier: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Bergdorf Bioscience (5mg SKU):** $119.99 USD standard list ($24.00/labeled mg; $107.99 USD / $21.60/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** Cagrilintide (AM833) is a lipidated long-acting amylin analogue with a ~180-hour (7.5-day) elimination half-life that activates both amylin (AMY1R–AMY3R) and calcitonin receptors in the area postrema, producing non-incretin satiety signaling. - **Titration & Dosing Schedule (5mg + 2mL BAC):** - Weeks 1–4: 0.25 mg (250 mcg) -> 10 Units on U-100 (0.100 mL) | 250 mcg initial amylin sensitization - Weeks 5–8: 0.5 mg (500 mcg) -> 20 Units on U-100 (0.200 mL) | 500 mcg step-up (once weekly) - Weeks 9–12: 1 mg (1000 mcg) -> 40 Units on U-100 (0.400 mL) | 1.0 mg intermediate tier - Weeks 13–16: 1.7 mg (1700 mcg) -> 68 Units on U-100 (0.680 mL) | 1.7 mg escalation tier - Weeks 17+: 2.4 mg (2400 mcg) -> 96 Units on U-100 (0.960 mL) | 2.4 mg REDEFINE trial ceiling - **Primary Literature Citations:** - Once-Weekly Subcutaneous Cagrilintide for Weight Management: A Phase 2 Trial (Lau et al.) — The Lancet (2021) · DOI: 10.1016/S0140-6736(21)01751-7 (https://doi.org/10.1016/S0140-6736(21)01751-7) - Concomitant Cagrilintide and Semaglutide 2.4 mg (CagriSema) Phase 1b Trial (Enebo et al.) — The Lancet (2021) · DOI: 10.1016/S0140-6736(21)00845-X (https://doi.org/10.1016/S0140-6736(21)00845-X) --- ## CagriSema Blend 10mg (5mg Cagrilintide + 5mg Semaglutide) - **Canonical Calculator URL:** https://peplab.wiki/compounds/cagrisema-blend-10mg - **Supported Vial Presets:** 5mg, 10mg (default) - **Category:** GLP-1 / Metabolic (1:1 Dual Amylin + GLP-1 Co-Formulation Blend) - **CAS Registry Number:** 1415456-99-3 / 910463-68-2 - **Molecular Weight:** 4409.01 + 4113.58 g/mol - **Sequence / Structure:** Dual 1:1 Lyophilized Peptide Co-Blend - **Pharmacokinetic Evidence Status:** 7 days (168 hours) | Recommended Interval: every 7 days - **Standard Reconstitution (10mg Vial + 2mL BAC Water):** Concentration = 5 mg/mL (50 mcg/unit). Initial 0.5 mg dose = 0.1 mL = **10 Units** on a U-100 syringe (20 doses/vial). - **Supplier $/mg Basis:** ~$8.19/mg est. (Simms Research, code PEPLAB10 — illustrative model estimate; verify live price on supplier site) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Clinical / Experimental Summary:** The CagriSema 10 mg blend pairs 5 mg Cagrilintide and 5 mg Semaglutide in an equal 1:1 mass ratio matching the Phase 3 REDEFINE-1 escalation ladder. Reconstituting 10 mg total in 2.0 mL BAC water (5.0 mg/mL total) means a 10-unit draw (0.10 mL) delivers 0.25 mg Cagrilintide + 0.25 mg Semaglutide (0.50 mg combined). - **Titration & Dosing Schedule (10mg + 2mL BAC):** - Weeks 1–4: 0.5 mg (500 mcg) -> 10 Units on U-100 (0.100 mL) | 0.25 mg Cagrilintide + 0.25 mg Semaglutide (10u at 2mL) - Weeks 5–8: 1 mg (1000 mcg) -> 20 Units on U-100 (0.200 mL) | 0.50 mg Cagrilintide + 0.50 mg Semaglutide (20u at 2mL) - Weeks 9–12: 2 mg (2000 mcg) -> 40 Units on U-100 (0.400 mL) | 1.0 mg Cagrilintide + 1.0 mg Semaglutide (40u at 2mL) - Weeks 13–16: 3.4 mg (3400 mcg) -> 68 Units on U-100 (0.680 mL) | 1.7 mg Cagrilintide + 1.7 mg Semaglutide (68u at 2mL) - Weeks 17+: 4.8 mg (4800 mcg) -> 96 Units on U-100 (0.960 mL) | 2.4 mg Cagrilintide + 2.4 mg Semaglutide (96u at 2mL) - **Primary Literature Citations:** - REDEFINE 1: A Research Study of CagriSema in People With Overweight or Obesity (NCT05567796) — ClinicalTrials.gov · NCT05567796 (https://clinicaltrials.gov/study/NCT05567796) - Efficacy and Safety of CagriSema 2.4 mg/2.4 mg in Type 2 Diabetes (Frias et al.) — The Lancet (2023) · DOI: 10.1016/S0140-6736(23)01163-7 (https://doi.org/10.1016/S0140-6736(23)01163-7) --- ## Survodutide (BI 456906 / Dual GCGR + GLP-1) - **Canonical Calculator URL:** https://peplab.wiki/compounds/survodutide - **Supported Vial Presets:** 5mg, 10mg (default), 15mg - **Category:** GLP-1 / Metabolic (Dual Glucagon / GLP-1 Receptor Agonist) - **CAS Registry Number:** 2805997-46-8 - **Molecular Weight:** 4231.70 g/mol - **Sequence / Structure:** 29 amino acids (acylatedoxyntomodulin analogue) - **Pharmacokinetic Evidence Status:** 4.6 days (110.4 hours) | Recommended Interval: every 7 days - **Standard Reconstitution (10mg Vial + 2mL BAC Water):** Concentration = 5 mg/mL (50 mcg/unit). Initial 0.6 mg dose = 0.12 mL = **12 Units** on a U-100 syringe (16.7 doses/vial). - **Supplier $/mg Basis:** $13.50/labeled mg documented (Bergdorf Bioscience, 10mg SKU = $149.99 USD list, $134.99 USD w/ BIO-QTVGWU, checked 2026-11-06) | Verifier: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Bergdorf Bioscience (10mg SKU):** $149.99 USD standard list ($15.00/labeled mg; $134.99 USD / $13.50/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** Survodutide (BI 456906) is an investigational dual glucagon receptor (GCGR) and GLP-1R agonist (approx. 1:8 GCGR:GLP-1R potency ratio) with a ~110-hour (4.6-day) half-life studied in the SYNCHRONIZE obesity and MASH liver fibrosis clinical trials. - **Titration & Dosing Schedule (10mg + 2mL BAC):** - Weeks 1–4: 0.6 mg (600 mcg) -> 12 Units on U-100 (0.120 mL) | 0.6 mg weekly initiation dose - Weeks 5–8: 1.2 mg (1200 mcg) -> 24 Units on U-100 (0.240 mL) | 1.2 mg weekly escalation step - Weeks 9–12: 2.4 mg (2400 mcg) -> 48 Units on U-100 (0.480 mL) | 2.4 mg intermediate metabolic tier - Weeks 13–16: 3.6 mg (3600 mcg) -> 72 Units on U-100 (0.720 mL) | 3.6 mg high-response tier - Weeks 17+: 4.8 mg (4800 mcg) -> 96 Units on U-100 (0.960 mL) | 4.8 mg maximum SYNCHRONIZE dose - **Primary Literature Citations:** - Survodutide, a Dual Glucagon/GLP-1 Receptor Agonist, for Obesity: A Phase 2 Trial (le Roux et al.) — The Lancet (2024) · DOI: 10.1016/S0140-6736(24)00405-9 (https://doi.org/10.1016/S0140-6736(24)00405-9) - A Phase 2 Trial of Survodutide in MASH and Liver Fibrosis (Sanyal et al.) — New England Journal of Medicine (2024) · DOI: 10.1056/NEJMoa2401755 (https://www.nejm.org/doi/full/10.1056/NEJMoa2401755) --- ## GLOW 70mg Blend (50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500) - **Canonical Calculator URL:** https://peplab.wiki/compounds/glow-blend-70mg - **Supported Vial Presets:** 70mg (default) - **Category:** Regenerative & Blend (5:1:1 Triple Regenerative Peptide Blend) - **CAS Registry Number:** 49557-75-7 / 137525-51-0 / 77591-33-4 - **Molecular Weight:** 403.92 + 1419.53 + 4963.50 g/mol - **Sequence / Structure:** Triple Lyophilized Formulation (70 mg Total) - **Pharmacokinetic Evidence Status:** 1 days (24 hours) | Recommended Interval: every 1 days - **Standard Reconstitution (70mg Vial + 3mL BAC Water):** Concentration = 23.33 mg/mL (233 mcg/unit). Initial 2.33 mg dose = 0.1 mL = **10 Units** on a U-100 syringe (30 doses/vial). - **Supplier $/mg Basis:** $1.23/labeled mg documented (Simms Research, 70mg SKU = $96.00 USD list, $86.40 USD w/ PEPLAB10, checked 2026-11-02) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (70mg SKU):** $96.00 USD standard list ($1.37/labeled mg; $86.40 USD / $1.23/mg 1st order w/ PEPLAB10) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Bergdorf Bioscience (70mg SKU):** $109.99 USD standard list ($1.57/labeled mg; $98.99 USD / $1.41/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** The 70 mg GLOW Blend combines 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500 in a single lyophilized vial (5:1:1 ratio). Reconstituting with 3.0 mL bacteriostatic water (23.33 mg/mL total) delivers 1.67 mg GHK-Cu + 333 mcg BPC-157 + 333 mcg TB-500 at 10 Units (0.10 mL), or exactly 2.0 mg GHK-Cu + 400 mcg BPC-157 + 400 mcg TB-500 at 12 Units (0.12 mL). - **Titration & Dosing Schedule (70mg + 3mL BAC):** - Low (9 Units / 0.09 mL): 2.1 mg (2100 mcg) -> 9 Units on U-100 (0.090 mL) | 1.50 mg GHK-Cu + 300 mcg BPC-157 + 300 mcg TB-500 (at 3.0 mL BAC) - Standard (10 Units / 0.10 mL): 2.33 mg (2330 mcg) -> 10 Units on U-100 (0.100 mL) | 1.67 mg GHK-Cu + 333 mcg BPC-157 + 333 mcg TB-500 (at 3.0 mL BAC) - Exact 2mg GHK (12 Units / 0.12 mL): 2.8 mg (2800 mcg) -> 12 Units on U-100 (0.120 mL) | 2.00 mg GHK-Cu + 400 mcg BPC-157 + 400 mcg TB-500 (25 doses/vial) - High (15 Units / 0.15 mL): 3.5 mg (3500 mcg) -> 15 Units on U-100 (0.150 mL) | 2.50 mg GHK-Cu + 500 mcg BPC-157 + 500 mcg TB-500 (20 doses/vial) - **Primary Literature Citations:** - Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (Pickart & Margolina) — International Journal of Molecular Sciences (2018) · PMC6073405 (https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/) - Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts (Chang et al.) — Molecules (2014) · PMC4231545 (https://pmc.ncbi.nlm.nih.gov/articles/PMC4231545/) - Thymosin Beta-4 Promotes Dermal Healing and Angiogenesis (Malinda et al.) — Journal of Investigative Dermatology (1999) · PMID: 10469335 (https://pubmed.ncbi.nlm.nih.gov/10469335/) --- ## KLOW 80mg Blend (50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500 + 10mg KPV) - **Canonical Calculator URL:** https://peplab.wiki/compounds/klow-blend-80mg - **Supported Vial Presets:** 80mg (default) - **Category:** Regenerative & Blend (5:1:1:1 Quad Regenerative & Anti-Inflammatory Blend) - **CAS Registry Number:** 49557-75-7 / 137525-51-0 / 77591-33-4 / 67727-97-3 - **Molecular Weight:** 403.92 + 1419.53 + 4963.50 + 342.44 g/mol - **Sequence / Structure:** Quad Lyophilized Formulation (80 mg Total) - **Pharmacokinetic Evidence Status:** 1 days (24 hours) | Recommended Interval: every 1 days - **Standard Reconstitution (80mg Vial + 3mL BAC Water):** Concentration = 26.67 mg/mL (267 mcg/unit). Initial 3.2 mg dose = 0.12 mL = **12 Units** on a U-100 syringe (25 doses/vial). - **Supplier $/mg Basis:** $1.37/labeled mg documented (Simms Research, 80mg SKU = $122.00 USD list, $109.80 USD w/ PEPLAB10, checked 2026-11-02) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (80mg SKU):** $122.00 USD standard list ($1.52/labeled mg; $109.80 USD / $1.37/mg 1st order w/ PEPLAB10) | COA Status: pdf_linked_metrics_unextracted (Lab Lot #2026-KW189, tested 2026-07-17, numeric purity/mass not yet extracted from linked PDF in snapshot) | COA PDF: https://simmsresearch.com/wp-content/uploads/2026/07/coa-klow-80mg-lot-2026-kw189-kovera-v2.pdf - **True Peptides (80mg SKU):** $124.00 USD standard list ($1.55/labeled mg) | COA Status: pdf_linked_metrics_unextracted (Lab Lot #260902, tested 2026-09-22, numeric purity/mass not yet extracted from linked PDF in snapshot) | COA PDF: https://cdn.true-peptides.com/coa/260902.pdf - **Clinical / Experimental Summary:** The 80 mg KLOW Blend adds 10 mg of the anti-inflammatory alpha-MSH C-terminal tripeptide KPV (Lys-Pro-Val) to the 70 mg GLOW formula (50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 + 10 mg KPV). Reconstituting with 3.0 mL BAC water (26.67 mg/mL) delivers exactly 2.0 mg GHK-Cu + 400 mcg BPC-157 + 400 mcg TB-500 + 400 mcg KPV at 12 Units (0.12 mL). - **Titration & Dosing Schedule (80mg + 3mL BAC):** - Low (9 Units / 0.09 mL): 2.4 mg (2400 mcg) -> 9 Units on U-100 (0.090 mL) | 1.50 mg GHK-Cu + 300 mcg each of BPC-157, TB-500, KPV - 10-Unit Draw (0.10 mL): 2.67 mg (2670 mcg) -> 10 Units on U-100 (0.100 mL) | 1.67 mg GHK-Cu + 333 mcg each of BPC-157, TB-500, KPV - Standard 12-Unit Draw (0.12 mL): 3.2 mg (3200 mcg) -> 12 Units on U-100 (0.120 mL) | 2.00 mg GHK-Cu + 400 mcg each of BPC-157, TB-500, KPV (25 doses) - High (15 Units / 0.15 mL): 4 mg (4000 mcg) -> 15 Units on U-100 (0.150 mL) | 2.50 mg GHK-Cu + 500 mcg each of BPC-157, TB-500, KPV (20 doses) - **Primary Literature Citations:** - PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal and Systemic Inflammation (Dalmasso et al.) — Gastroenterology (2008) · PMC2431115 (https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/) - Regenerative and Protective Actions of the GHK-Cu Peptide (Pickart & Margolina) — International Journal of Molecular Sciences (2018) · PMC6073405 (https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/) --- ## Wolverine Stack 20mg Blend (10mg BPC-157 + 10mg TB-500) - **Canonical Calculator URL:** https://peplab.wiki/compounds/wolverine-stack-10mg - **Supported Vial Presets:** 10mg, 20mg (default) - **Category:** Regenerative & Blend (1:1 Dual Tendon & Connective Tissue Blend) - **CAS Registry Number:** 137525-51-0 / 885340-08-9 (or 77591-33-4) - **Molecular Weight:** 1419.53 + 889.01 (7-AA) or 4963.50 (43-AA) g/mol - **Sequence / Structure:** Dual 1:1 Lyophilized Formulation (20 mg Standard / 10 mg Custom) - **Chemical Form & Counter-Ion Basis:** Supplier catalog reconciliation (2026-11-04): Both Simms Research and True Peptides (SKU TP-BT20) supply this blend as a 20 mg total lyophilized vial (10 mg BPC-157 + 10 mg TB-500). Chemical identity note: Simms Research specifies the 7-amino-acid actin-binding fragment Ac-LKKTETQ-OH (Thymosin Beta-4 [17–23], C38H68N10O14, MW 889.01 g/mol, CAS 885340-08-9) for its TB-500 constituent, whereas full-length 43-amino-acid Thymosin Beta-4 has formula C212H350N56O78S (MW 4963.50 g/mol, CAS 77591-33-4). True Peptides publishes Optiq Health Labs Lot #260903 (COA UID: 1458.OPT.260918-R1, reported 2026-09-22) reporting 99.4% RP-HPLC purity and LC-MS identity confirmation for BPC-157 + TB-500; quantitative mg/vial net content and the 10 mg + 10 mg constituent mass ratio are not separately quantified on the public certificate. - **Pharmacokinetic Evidence Status:** Human subcutaneous pharmacokinetic parameters insufficiently established in published literature (multi-day accumulation curve and clearance modeling omitted) — A co-lyophilized multi-peptide blend combining BPC-157 and TB-500 (or its 7-AA fragment Ac-LKKTETQ-OH) does not possess a single unified human subcutaneous terminal half-life or validated co-formulation pharmacokinetic superposition profile. Published preclinical studies evaluate the individual constituent peptides separately (Chang et al., 2011; Malinda et al., 1999). Multi-day single-curve pharmacokinetic superposition graphing is therefore omitted. - **Hypothetical Reconstitution & Aliquot Arithmetic (20mg Vial + 2mL BAC Water):** Concentration = 10 mg/mL (100 mcg/unit). A hypothetical 0.5 mg aliquot equals 0.05 mL = **5 Units** on a U-100 syringe (40 aliquots/vial). - **Supplier $/mg Basis:** $3.56/labeled mg documented (Simms Research, 20mg SKU = $79.00 USD list, $71.10 USD w/ PEPLAB10, checked 2026-11-04) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (20mg SKU):** $79.00 USD standard list ($3.95/labeled mg; $71.10 USD / $3.56/mg 1st order w/ PEPLAB10) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **True Peptides (20mg SKU):** $110.00 USD standard list ($5.50/labeled mg) | COA Status: purity_only_pdf_linked (Optiq Health Labs, LLC Lot #260903, tested 2026-09-22, RP-HPLC purity 99.4%, net mass not reported on certificate) | COA PDF: https://cdn.true-peptides.com/coa/260903.pdf - **Bergdorf Bioscience (20mg SKU):** $113.99 USD standard list ($5.70/labeled mg; $102.59 USD / $5.13/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** The Wolverine 20 mg Blend combines 10 mg BPC-157 and 10 mg TB-500 in an equal 1:1 mass ratio (matching current 20 mg supplier vials; 10 mg [5 mg + 5 mg] preset also supported). Reconstituting a 20 mg vial with 2.0 mL bacteriostatic water yields 10.0 mg/mL total (5.0 mg/mL of each peptide), so a 5-unit draw (0.05 mL) delivers 250 mcg BPC-157 + 250 mcg TB-500 (0.50 mg combined) and a 10-unit draw (0.10 mL) delivers 500 mcg + 500 mcg (1.0 mg combined). - **Dosing Evidence Boundary:** Hypothetical volumetric aliquot arithmetic only (0.50 mg and 1.00 mg combined mass-to-volume conversions for a 20 mg [10 mg + 10 mg] or 10 mg [5 mg + 5 mg] vial reconstituted with 2.0 mL bacteriostatic water). No FDA-approved or clinically validated human co-formulation dosing regimen exists for a combined BPC-157 + TB-500 blend. - **Hypothetical Volumetric Aliquot Conversions (Non-Clinical Arithmetic Only) (20mg + 2mL BAC):** - 0.50 mg Combined Aliquot (250 mcg + 250 mcg): 0.5 mg (500 mcg) -> 5 Units on U-100 (0.050 mL) | 0.50 mg ÷ 10.0 mg/mL = 0.05 mL = 5 units on U-100 at 20mg/2mL (or 10 units at 10mg/2mL; 40 aliquots per 20mg vial; hypothetical dilution arithmetic only) - 1.00 mg Combined Aliquot (500 mcg + 500 mcg): 1 mg (1000 mcg) -> 10 Units on U-100 (0.100 mL) | 1.00 mg ÷ 10.0 mg/mL = 0.10 mL = 10 units on U-100 at 20mg/2mL (or 20 units at 10mg/2mL; 20 aliquots per 20mg vial; hypothetical dilution arithmetic only) - **Primary Literature Citations:** - The Promoting Effect of Pentadecapeptide BPC 157 on Tendon Healing (Chang et al.) — Journal of Applied Physiology (2011) · PMID: 21030672 (https://pubmed.ncbi.nlm.nih.gov/21030672/) - Thymosin Beta-4 Accelerates Wound Healing (Malinda et al.) — Journal of Investigative Dermatology (1999) · PMID: 10469335 (https://pubmed.ncbi.nlm.nih.gov/10469335/) --- ## BPC-157 (Pentadecapeptide Body Protection Compound) - **Canonical Calculator URL:** https://peplab.wiki/compounds/bpc-157 - **Supported Vial Presets:** 5mg (default), 10mg, 15mg - **Category:** Regenerative & Blend (Tendon, Ligament & Mucosal Cytoprotective Peptide) - **CAS Registry Number:** 137525-51-0 - **Molecular Weight:** 1419.53 g/mol - **Sequence / Structure:** 15 amino acids (GEPPPGKPADDAGLV) - **Pharmacokinetic Evidence Status:** 0.25 days (6 hours) | Recommended Interval: every 1 days - **Standard Reconstitution (5mg Vial + 2mL BAC Water):** Concentration = 2.5 mg/mL (25 mcg/unit). Initial 0.25 mg dose = 0.1 mL = **10 Units** on a U-100 syringe (20 doses/vial). - **Supplier $/mg Basis:** $6.21/labeled mg documented (Simms Research, 10mg SKU = $69.00 USD list, $62.10 USD w/ PEPLAB10, checked 2026-11-02) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (10mg SKU):** $69.00 USD standard list ($6.90/labeled mg; $62.10 USD / $6.21/mg 1st order w/ PEPLAB10) | COA Status: sample_size_mismatch_pdf_linked (Lab Lot #2026-B670, tested 2026-07-16, net mass not reported on certificate) | COA PDF: https://simmsresearch.com/wp-content/uploads/2026/07/coa-bpc-157-10mg-lot-2026-b670-kovera-v2.pdf - **True Peptides (5mg SKU):** $44.00 USD standard list ($8.80/labeled mg) | COA Status: sample_size_mismatch_pdf_linked (Lab Lot #260835, tested 2026-08-12, net mass not reported on certificate) | COA PDF: https://cdn.true-peptides.com/coa/260835.pdf - **Bergdorf Bioscience (5mg SKU):** $76.99 USD standard list ($15.40/labeled mg; $69.29 USD / $13.86/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** BPC-157 is a synthetic 15-amino-acid pentadecapeptide researched for VEGF angiogenesis upregulation, tendon-to-bone fibroblast migration, and gastrointestinal mucosal repair. In a 5 mg vial mixed with 2.0 mL BAC water (2.5 mg/mL), a 250 mcg (0.25 mg) dose equals exactly 10 Units on a U-100 syringe. - **Titration & Dosing Schedule (5mg + 2mL BAC):** - Weeks 1–4 (Once Daily): 0.25 mg (250 mcg) -> 10 Units on U-100 (0.100 mL) | 250 mcg (0.25 mg = 10 units at 2.5 mg/mL) once daily - Weeks 5–8 (Twice Daily Total): 0.5 mg (500 mcg) -> 20 Units on U-100 (0.200 mL) | 500 mcg total daily (250 mcg AM + 250 mcg PM) - **Primary Literature Citations:** - The Promoting Effect of Pentadecapeptide BPC 157 on Tendon Healing Involves Tendon Outgrowth, Cell Survival, and Cell Migration — Journal of Applied Physiology (2011) · PMID: 21030672 (https://pubmed.ncbi.nlm.nih.gov/21030672/) - Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts — Molecules (2014) · PMC4231545 (https://pmc.ncbi.nlm.nih.gov/articles/PMC4231545/) --- ## TB-500 (Thymosin Beta-4 / Ac-LKKTETQ-OH Active Fragment) - **Canonical Calculator URL:** https://peplab.wiki/compounds/tb-500 - **Supported Vial Presets:** 5mg, 10mg (default) - **Category:** Regenerative & Blend (Actin-Sequestering & Cellular Migration Peptide) - **CAS Registry Number:** 77591-33-4 (43-AA Tβ4) / 885340-08-9 (7-AA Fragment) - **Molecular Weight:** 4963.50 g/mol (43-AA) / 889.01 g/mol (7-AA Ac-LKKTETQ-OH) - **Sequence / Structure:** 43 amino acids (or 7-AA Ac-LKKTETQ-OH fragment) - **Chemical Form & Counter-Ion Basis:** Chemical identity note: In research peptide catalogs, "TB-500" may designate either full-length 43-amino-acid Thymosin Beta-4 (C212H350N56O78S, MW 4963.50 g/mol, CAS 77591-33-4) or its N-acetylated 7-amino-acid actin-binding fragment Ac-LKKTETQ-OH (Thymosin Beta-4 [17–23], C38H68N10O14, MW 889.01 g/mol, CAS 885340-08-9; explicitly listed by Simms Research). Because molecular weight differs 5.6-fold between the heptapeptide fragment and full-length polypeptide, researchers should verify the exact sequence and molecular ion (m/z) on the lot-specific LC-MS Certificate of Analysis. - **Pharmacokinetic Evidence Status:** 2.5 days (60 hours) | Recommended Interval: every 3.5 days - **Standard Reconstitution (10mg Vial + 2mL BAC Water):** Concentration = 5 mg/mL (50 mcg/unit). Initial 2 mg dose = 0.4 mL = **40 Units** on a U-100 syringe (5 doses/vial). - **Supplier $/mg Basis:** $5.94/labeled mg documented (Simms Research, 10mg SKU = $66.00 USD list, $59.40 USD w/ PEPLAB10, checked 2026-11-02) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (10mg SKU):** $66.00 USD standard list ($6.60/labeled mg; $59.40 USD / $5.94/mg 1st order w/ PEPLAB10) | COA Status: pdf_linked_metrics_unextracted (Lab Lot #2026-TB209, tested 2026-07-16, numeric purity/mass not yet extracted from linked PDF in snapshot) | COA PDF: https://simmsresearch.com/wp-content/uploads/2026/10/coa-tb-500-10mg-lot-2026-tb209-kovera-v2.pdf - **True Peptides (10mg SKU):** $61.00 USD standard list ($6.10/labeled mg) | COA Status: sample_size_mismatch_pdf_linked (Lab Lot #261003, tested 2026-10-14, net mass not reported on certificate) | COA PDF: https://cdn.true-peptides.com/coa/261003.pdf - **Bergdorf Bioscience (10mg SKU):** $89.99 USD standard list ($9.00/labeled mg; $80.99 USD / $8.10/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** TB-500 is the synthetic version of Thymosin Beta-4 that regulates G-actin polymerization, endothelial cell migration, and myofibroblast differentiation. Because of its ~2.5-day systemic half-life, standard protocols use a twice-weekly loading phase (2.0–2.5 mg per pin) followed by weekly maintenance. - **Titration & Dosing Schedule (10mg + 2mL BAC):** - Weeks 1–6 (Loading Phase): 2 mg (2000 mcg) -> 40 Units on U-100 (0.400 mL) | 2.0 mg twice weekly (4.0 mg/week total; 40 units per pin at 5 mg/mL) - Weeks 7–12 (Maintenance): 1 mg (1000 mcg) -> 20 Units on U-100 (0.200 mL) | 1.0 mg to 2.0 mg once weekly maintenance - **Primary Literature Citations:** - Thymosin Beta-4 and the Eye: I. Thymosin Beta-4 Promotes Corneal Re-Epithelialization (Sosne et al.) — Experimental Eye Research (2001) · PMID: 11428863 (https://pubmed.ncbi.nlm.nih.gov/11428863/) - Thymosin Beta-4 Accelerates Wound Healing (Malinda et al.) — Journal of Investigative Dermatology (1999) · PMID: 10469335 (https://pubmed.ncbi.nlm.nih.gov/10469335/) --- ## GHK-Cu (Copper Tripeptide-1 Lyophilized) - **Canonical Calculator URL:** https://peplab.wiki/compounds/ghk-cu - **Supported Vial Presets:** 50mg (default), 75mg, 100mg - **Category:** Regenerative & Blend (Extracellular Matrix & Gene Expression Remodeler) - **CAS Registry Number:** 49557-75-7 - **Molecular Weight:** 403.92 g/mol - **Sequence / Structure:** 3 amino acids (Gly-His-Lys : Cu2+ complex) - **Pharmacokinetic Evidence Status:** 0.5 days (12 hours) | Recommended Interval: every 1 days - **Standard Reconstitution (50mg Vial + 3mL BAC Water):** Concentration = 16.67 mg/mL (167 mcg/unit). Initial 2 mg dose = 0.12 mL = **12 Units** on a U-100 syringe (25 doses/vial). - **Supplier $/mg Basis:** $0.86/labeled mg documented (Simms Research, 50mg SKU = $48.00 USD list, $43.20 USD w/ PEPLAB10, checked 2026-11-02) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (50mg SKU):** $48.00 USD standard list ($0.96/labeled mg; $43.20 USD / $0.86/mg 1st order w/ PEPLAB10) | COA Status: pdf_linked_metrics_unextracted (Lab Lot #2026-GH612, tested 2026-07-16, numeric purity/mass not yet extracted from linked PDF in snapshot) | COA PDF: https://simmsresearch.com/wp-content/uploads/2026/07/coa-ghk-cu-50mg-lot-2026-gh612-kovera-v2.pdf - **True Peptides (50mg SKU):** $40.00 USD standard list ($0.80/labeled mg) | COA Status: pdf_linked_metrics_unextracted (Lab Lot #260911, tested 2026-09-22, numeric purity/mass not yet extracted from linked PDF in snapshot) | COA PDF: https://cdn.true-peptides.com/coa/260911.pdf - **Bergdorf Bioscience (50mg SKU):** $39.99 USD standard list ($0.80/labeled mg; $35.99 USD / $0.72/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** GHK-Cu is a naturally occurring human plasma copper tripeptide complex shown in Broad Institute Connectivity Map studies to modulate over 4,000 human genes involved in collagen synthesis, glycosaminoglycan deposition, and antioxidant defense. A 50 mg vial diluted with 3.0 mL BAC water yields 16.67 mg/mL (2.0 mg = 12 Units on U-100). - **Titration & Dosing Schedule (50mg + 3mL BAC):** - Initiation (Weeks 1–2): 1.5 mg (1500 mcg) -> 9 Units on U-100 (0.090 mL) | 1.5 mg daily (9 units on U-100 at 50mg + 3mL dilution) - Standard Cycle (Weeks 3–6): 2 mg (2000 mcg) -> 12 Units on U-100 (0.120 mL) | 2.0 mg daily (12 units on U-100 at 50mg + 3mL dilution) - **Primary Literature Citations:** - Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (Pickart & Margolina) — International Journal of Molecular Sciences (2018) · PMC6073405 (https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/) - GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration (Pickart et al.) — BioMed Research International (2015) · PMC4508379 (https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/) --- ## CJC-1295 No DAC (Mod GRF 1-29) + Ipamorelin 10mg Blend - **Canonical Calculator URL:** https://peplab.wiki/compounds/cjc-ipamorelin-blend-10mg - **Supported Vial Presets:** 10mg (default) - **Category:** GH Secretagogue (1:1 Synergistic GHRH + Ghrelin Mimetic Blend) - **CAS Registry Number:** 863288-34-0 / 170851-70-4 - **Molecular Weight:** 3367.97 + 711.85 g/mol - **Sequence / Structure:** 29-AA Mod GRF + 5-AA Ipamorelin (5mg + 5mg) - **Chemical Form & Counter-Ion Basis:** Analytical verification note (2026-11-04): True Peptides (SKU TP-CI10) publishes Optiq Health Labs Lot #260905 (COA UID: 1460.OPT.260918-R1, reported 2026-09-22) reporting 99.6% RP-HPLC purity and LC-MS identity confirmation for CJC-1295 No DAC (Mod GRF 1-29, CAS 863288-34-0) + Ipamorelin (CAS 170851-70-4); quantitative mg/vial net content and the 5 mg + 5 mg constituent mass ratio are not separately quantified on the public certificate. Simms Research lists a 10 mg (5 mg + 5 mg) blend vial with no public batch COA located as of 2026-11-04. - **Pharmacokinetic Evidence Status:** Human subcutaneous pharmacokinetic parameters insufficiently established in published literature (multi-day accumulation curve and clearance modeling omitted) — A co-lyophilized multi-peptide blend combining CJC-1295 without DAC (Modified GRF 1-29) and Ipamorelin does not possess a single unified human subcutaneous terminal half-life or validated co-formulation pharmacokinetic accumulation curve. Published endocrine literature characterizes the individual GHRH and GHRP constituents separately (Raun et al., 1998; Teichman et al., 2006). Multi-day single-curve pharmacokinetic superposition graphing is therefore omitted. - **Hypothetical Reconstitution & Aliquot Arithmetic (10mg Vial + 2.5mL BAC Water):** Concentration = 4 mg/mL (40 mcg/unit). A hypothetical 0.2 mg aliquot equals 0.05 mL = **5 Units** on a U-100 syringe (50 aliquots/vial). - **Supplier $/mg Basis:** $7.02/labeled mg documented (Simms Research, 10mg SKU = $78.00 USD list, $70.20 USD w/ PEPLAB10, checked 2026-11-04) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (10mg SKU):** $78.00 USD standard list ($7.80/labeled mg; $70.20 USD / $7.02/mg 1st order w/ PEPLAB10) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **True Peptides (10mg SKU):** $89.00 USD standard list ($8.90/labeled mg) | COA Status: purity_only_pdf_linked (Optiq Health Labs, LLC Lot #260905, tested 2026-09-22, RP-HPLC purity 99.6%, net mass not reported on certificate) | COA PDF: https://cdn.true-peptides.com/coa/260905.pdf - **Bergdorf Bioscience (10mg SKU):** $124.99 USD standard list ($12.50/labeled mg; $112.49 USD / $11.25/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** Combines 5 mg CJC-1295 without DAC (Modified GRF 1-29, GHRH receptor agonist) and 5 mg Ipamorelin (selective ghrelin/GHS-R1a agonist) in a 10 mg vial. Reconstituting with 2.5 mL BAC water yields 4.0 mg/mL total (2.0 mg/mL each), so a 5-unit draw (0.05 mL) delivers exactly 100 mcg Mod GRF 1-29 + 100 mcg Ipamorelin (0.20 mg total). - **Dosing Evidence Boundary:** Hypothetical volumetric aliquot arithmetic only (0.20 mg and 0.40 mg combined mass-to-volume conversions for a 10 mg [5 mg + 5 mg] vial reconstituted with 2.5 mL bacteriostatic water = 4.0 mg/mL total). No FDA-approved or clinically validated human co-formulation dosing regimen exists for a combined CJC-1295 No DAC + Ipamorelin vial. - **Hypothetical Volumetric Aliquot Conversions (Non-Clinical Arithmetic Only) (10mg + 2.5mL BAC):** - 0.20 mg Combined Aliquot (100 mcg + 100 mcg): 0.2 mg (200 mcg) -> 5 Units on U-100 (0.050 mL) | 0.20 mg ÷ 4.0 mg/mL = 0.05 mL = 5 units on U-100 at 10mg/2.5mL (50 aliquots per 10mg vial; hypothetical dilution arithmetic only) - 0.40 mg Combined Aliquot (200 mcg + 200 mcg): 0.4 mg (400 mcg) -> 10 Units on U-100 (0.100 mL) | 0.40 mg ÷ 4.0 mg/mL = 0.10 mL = 10 units on U-100 at 10mg/2.5mL (25 aliquots per 10mg vial; hypothetical dilution arithmetic only) - **Primary Literature Citations:** - Ipamorelin, the First Selective Growth Hormone Secretagogue (Raun et al.) — European Journal of Endocrinology (1998) · PMID: 9849822 (https://pubmed.ncbi.nlm.nih.gov/9849822/) - Pulsatile Secretion of Growth Hormone and GHRH Analogue Synergy (Teichman et al.) — Journal of Clinical Endocrinology & Metabolism (2006) · PMID: 16352683 (https://pubmed.ncbi.nlm.nih.gov/16352683/) --- ## Tesamorelin (TH9507 Stabilized GHRH Analogue) - **Canonical Calculator URL:** https://peplab.wiki/compounds/tesamorelin - **Supported Vial Presets:** 2mg, 5mg, 10mg (default) - **Category:** GH Secretagogue (Growth Hormone-Releasing Hormone (GHRH 1-44) Analogue) - **CAS Registry Number:** 218949-48-5 - **Molecular Weight:** 5135.86 g/mol - **Sequence / Structure:** 44 amino acids (N-terminal trans-3-hexenoyl group) - **Pharmacokinetic Evidence Status:** 0.5 days (12 hours) | Recommended Interval: every 1 days - **Standard Reconstitution (10mg Vial + 2mL BAC Water):** Concentration = 5 mg/mL (50 mcg/unit). Initial 1 mg dose = 0.2 mL = **20 Units** on a U-100 syringe (10 doses/vial). - **Supplier $/mg Basis:** $8.55/labeled mg documented (Simms Research, 10mg SKU = $95.00 USD list, $85.50 USD w/ PEPLAB10, checked 2026-11-02) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (10mg SKU):** $95.00 USD standard list ($9.50/labeled mg; $85.50 USD / $8.55/mg 1st order w/ PEPLAB10) | COA Status: pdf_linked_metrics_unextracted (Lab Lot #2026-TN650, tested 2026-07-16, numeric purity/mass not yet extracted from linked PDF in snapshot) | COA PDF: https://simmsresearch.com/wp-content/uploads/2026/07/coa-tesamorelin-10mg-lot-2026-tn650-kovera-v2.pdf - **True Peptides (10mg SKU):** $81.00 USD standard list ($8.10/labeled mg) | COA Status: purity_only_pdf_linked (Optiq Health Labs, LLC Lot #260904, tested 2026-09-22, RP-HPLC purity 99.1%, net mass not reported on certificate) | COA PDF: https://cdn.true-peptides.com/coa/260904.pdf - **Bergdorf Bioscience (10mg SKU):** $109.99 USD standard list ($11.00/labeled mg; $98.99 USD / $9.90/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** Tesamorelin (TH9507) is a DPP-4-resistant 44-amino-acid human GHRH analogue clinically demonstrated in NEJM randomized trials (Falutz et al.) to selectively reduce visceral adipose tissue (VAT) by 15–18% and hepatic fat fraction while preserving physiological GH pulsatility. - **Titration & Dosing Schedule (10mg + 2mL BAC):** - Weeks 1–4 (Research Initiation): 1 mg (1000 mcg) -> 20 Units on U-100 (0.200 mL) | 1.0 mg daily subcutaneous administration pre-bedtime (20 units at 5 mg/mL) - Weeks 5–26 (Clinical Label Dose): 2 mg (2000 mcg) -> 40 Units on U-100 (0.400 mL) | 2.0 mg daily standard NEJM trial dose (40 units at 5 mg/mL) - **Primary Literature Citations:** - Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV (Falutz et al.) — New England Journal of Medicine (2007) · DOI: 10.1056/NEJMoa072375 (https://www.nejm.org/doi/full/10.1056/NEJMoa072375) - Effects of Tesamorelin on Visceral Fat and Liver Fat in NAFLD (Stanley et al.) — The Lancet HIV (2019) · PMC6917047 (https://pmc.ncbi.nlm.nih.gov/articles/PMC6917047/) --- ## Ipamorelin (Selective Pentapeptide GH Secretagogue) - **Canonical Calculator URL:** https://peplab.wiki/compounds/ipamorelin - **Supported Vial Presets:** 5mg (default), 10mg - **Category:** GH Secretagogue (Selective GHS-R1a Ghrelin Receptor Agonist) - **CAS Registry Number:** 170851-70-4 - **Molecular Weight:** 711.85 g/mol - **Sequence / Structure:** 5 amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2) - **Pharmacokinetic Evidence Status:** 0.25 days (6 hours) | Recommended Interval: every 1 days - **Standard Reconstitution (5mg Vial + 2.5mL BAC Water):** Concentration = 2 mg/mL (20 mcg/unit). Initial 0.25 mg dose = 0.125 mL = **12.5 Units** on a U-100 syringe (20 doses/vial). - **Supplier $/mg Basis:** $6.66/labeled mg documented (Simms Research, 10mg SKU = $74.00 USD list, $66.60 USD w/ PEPLAB10, checked 2026-11-02) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (10mg SKU):** $74.00 USD standard list ($7.40/labeled mg; $66.60 USD / $6.66/mg 1st order w/ PEPLAB10) | COA Status: sample_size_mismatch_pdf_linked (Lab Lot #2026-IN390, tested 2026-07-16, net mass not reported on certificate) | COA PDF: https://simmsresearch.com/wp-content/uploads/2026/07/coa-ipamorelin-10mg-lot-2026-in390-kovera-v2.pdf - **True Peptides (5mg SKU):** $45.00 USD standard list ($9.00/labeled mg) | COA Status: sample_size_mismatch_pdf_linked (Lab Lot #260909, tested 2026-09-22, net mass not reported on certificate) | COA PDF: https://cdn.true-peptides.com/coa/260909.pdf - **Bergdorf Bioscience (10mg SKU):** $109.99 USD standard list ($11.00/labeled mg; $98.99 USD / $9.90/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively stimulates pituitary somatotrophs without significantly elevating ACTH, cortisol, prolactin, or aldosterone. A 5 mg vial diluted with 2.5 mL BAC water yields 2.0 mg/mL (200 mcg = 10 Units on U-100). - **Titration & Dosing Schedule (5mg + 2.5mL BAC):** - Weeks 1–4 (200 mcg Nightly): 0.2 mg (200 mcg) -> 10 Units on U-100 (0.100 mL) | 200 mcg (0.20 mg = 10 units at 2.0 mg/mL) fasted before sleep - Weeks 5–12 (250–300 mcg): 0.25 mg (250 mcg) -> 12.5 Units on U-100 (0.125 mL) | 250 mcg (0.25 mg = 12.5 units at 2.0 mg/mL) daily - **Primary Literature Citations:** - Ipamorelin, the First Selective Growth Hormone Secretagogue (Raun et al.) — European Journal of Endocrinology (1998) · PMID: 9849822 (https://pubmed.ncbi.nlm.nih.gov/9849822/) - Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers (Gobburu et al.) — Pharmaceutical Research (1999) · PMID: 10496658 (https://pubmed.ncbi.nlm.nih.gov/10496658/) --- ## MOTS-c (Mitochondrial-Derived 12S rRNA Peptide) - **Canonical Calculator URL:** https://peplab.wiki/compounds/mots-c - **Supported Vial Presets:** 5mg, 10mg (default) - **Category:** Longevity & Neuro (Mitochondrial AMPK & Folate-Methionine Regulator) - **CAS Registry Number:** 1627580-64-6 - **Molecular Weight:** 2174.60 g/mol - **Sequence / Structure:** 16 amino acids (MRWQEMGYIFYPRKLR) - **Pharmacokinetic Evidence Status:** 1.5 days (36 hours) | Recommended Interval: every 2.5 days - **Standard Reconstitution (10mg Vial + 2mL BAC Water):** Concentration = 5 mg/mL (50 mcg/unit). Initial 5 mg dose = 1 mL = **100 Units** on a U-100 syringe (2 doses/vial). - **Supplier $/mg Basis:** $5.85/labeled mg documented (Simms Research, 10mg SKU = $65.00 USD list, $58.50 USD w/ PEPLAB10, checked 2026-11-02) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (10mg SKU):** $65.00 USD standard list ($6.50/labeled mg; $58.50 USD / $5.85/mg 1st order w/ PEPLAB10) | COA Status: pdf_linked_metrics_unextracted (Lab Lot #2026-MO387, tested 2026-07-16, numeric purity/mass not yet extracted from linked PDF in snapshot) | COA PDF: https://simmsresearch.com/wp-content/uploads/2026/07/coa-mots-c-10mg-lot-2026-mo387-kovera-v2.pdf - **True Peptides (10mg SKU):** $63.00 USD standard list ($6.30/labeled mg) | COA Status: pdf_linked_metrics_unextracted (Lab Lot #260834, tested 2026-08-12, numeric purity/mass not yet extracted from linked PDF in snapshot) | COA PDF: https://cdn.true-peptides.com/coa/260834.pdf - **Bergdorf Bioscience (10mg SKU):** $79.99 USD standard list ($8.00/labeled mg; $71.99 USD / $7.20/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA short open reading frame that translocates to the nucleus under metabolic stress to regulate AICAR-AMPK signaling, GLUT4 glucose disposal, and skeletal muscle homeostasis. - **Titration & Dosing Schedule (10mg + 2mL BAC):** - Weeks 1–2 (Acclimation): 2.5 mg (2500 mcg) -> 50 Units on U-100 (0.500 mL) | 2.5 mg (50 units at 5 mg/mL) twice weekly - Weeks 3–6 (Standard Protocol): 5 mg (5000 mcg) -> 100 Units on U-100 (1.000 mL) | 5.0 mg (100 units at 5 mg/mL) 2 to 3 times weekly pre-exercise - **Primary Literature Citations:** - The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance (Lee et al.) — Cell Metabolism (2015) · PMC4350682 (https://pmc.ncbi.nlm.nih.gov/articles/PMC4350682/) - MOTS-c is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline (Reynolds et al.) — Nature Communications (2021) · PMC7817689 (https://pmc.ncbi.nlm.nih.gov/articles/PMC7817689/) --- ## NAD+ 500mg (Nicotinamide Adenine Dinucleotide Lyophilized) - **Canonical Calculator URL:** https://peplab.wiki/compounds/nad-plus - **Supported Vial Presets:** 100mg, 250mg, 500mg (default), 1000mg - **Category:** Longevity & Neuro (Cellular Redox Coenzyme & Sirtuin (SIRT1-7) Substrate) - **CAS Registry Number:** 53-84-9 - **Molecular Weight:** 663.43 g/mol - **Sequence / Structure:** Dinucleotide Coenzyme (C21H27N7O14P2) - **Pharmacokinetic Evidence Status:** 1 days (24 hours) | Recommended Interval: every 2 days - **Standard Reconstitution (500mg Vial + 5mL BAC Water):** Concentration = 100 mg/mL (1000 mcg/unit). Initial 50 mg dose = 0.5 mL = **50 Units** on a U-100 syringe (10 doses/vial). - **Supplier $/mg Basis:** $0.14/labeled mg documented (Simms Research, 500mg SKU = $76.00 USD list, $68.40 USD w/ PEPLAB10, checked 2026-11-02) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (500mg SKU):** $76.00 USD standard list ($0.15/labeled mg; $68.40 USD / $0.14/mg 1st order w/ PEPLAB10) | COA Status: pdf_linked_metrics_unextracted (Lab Lot #2026-N299, tested 2026-07-16, numeric purity/mass not yet extracted from linked PDF in snapshot) | COA PDF: https://simmsresearch.com/wp-content/uploads/2026/07/coa-nad-plus-500mg-lot-2026-n299-kovera-v2.pdf - **True Peptides (500mg SKU):** $81.00 USD standard list ($0.16/labeled mg) | COA Status: pdf_linked_metrics_unextracted (Lab Lot #260910, tested 2026-09-22, numeric purity/mass not yet extracted from linked PDF in snapshot) | COA PDF: https://cdn.true-peptides.com/coa/260910.pdf - **Bergdorf Bioscience (1000mg SKU):** $129.99 USD standard list ($0.13/labeled mg; $116.99 USD / $0.12/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** Lyophilized NAD+ (500 mg and 1,000 mg vials) requires high-volume dilution (typically 5.0 mL bacteriostatic water for a 500 mg vial = 100 mg/mL) so that 25 mg to 100 mg subcutaneous doses correspond cleanly to 25 to 100 Units on a standard U-100 syringe. - **Titration & Dosing Schedule (500mg + 5mL BAC):** - Weeks 1–2 (Titration): 25 mg (25000 mcg) -> 25 Units on U-100 (0.250 mL) | 25 mg (25 units at 100 mg/mL) 2–3x weekly - Weeks 3–8 (Standard Maintenance): 50 mg (50000 mcg) -> 50 Units on U-100 (0.500 mL) | 50 mg (50 units at 100 mg/mL) 2–3x weekly - Weeks 9+ (High Bioenergetic Tier): 100 mg (100000 mcg) -> 100 Units on U-100 (1.000 mL) | 100 mg (100 units / 1.0 mL at 100 mg/mL) twice weekly - **Primary Literature Citations:** - NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus (Canto et al.) — Cell Metabolism (2015) · PMC4487780 (https://pmc.ncbi.nlm.nih.gov/articles/PMC4487780/) - A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+ (Grant et al.) — Frontiers in Aging Neuroscience (2019) · PMC6751128 (https://pmc.ncbi.nlm.nih.gov/articles/PMC6751128/) --- ## Epithalon (AEDG Synthetic Pineal Tetrapeptide) - **Canonical Calculator URL:** https://peplab.wiki/compounds/epithalon - **Supported Vial Presets:** 10mg (default), 20mg, 50mg - **Category:** Longevity & Neuro (Telomerase Activator & Pineal Circadian Tetrapeptide) - **CAS Registry Number:** 307297-39-8 - **Molecular Weight:** 390.35 g/mol - **Sequence / Structure:** 4 amino acids (Ala-Glu-Asp-Gly) - **Pharmacokinetic Evidence Status:** 0.5 days (12 hours) | Recommended Interval: every 1 days - **Standard Reconstitution (10mg Vial + 2mL BAC Water):** Concentration = 5 mg/mL (50 mcg/unit). Initial 1 mg dose = 0.2 mL = **20 Units** on a U-100 syringe (10 doses/vial). - **Supplier $/mg Basis:** $5.31/labeled mg documented (Simms Research, 10mg SKU = $59.00 USD list, $53.10 USD w/ PEPLAB10, checked 2026-11-02) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (10mg SKU):** $59.00 USD standard list ($5.90/labeled mg; $53.10 USD / $5.31/mg 1st order w/ PEPLAB10) | COA Status: pdf_linked_metrics_unextracted (Lab Lot #2026-EN247, tested 2026-07-16, numeric purity/mass not yet extracted from linked PDF in snapshot) | COA PDF: https://simmsresearch.com/wp-content/uploads/2026/07/coa-epithalon-10mg-lot-2026-en247-kovera-v2.pdf - **True Peptides (10mg SKU):** $43.00 USD standard list ($4.30/labeled mg) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://true-peptides.com/coas?ref=peplab - **Bergdorf Bioscience (10mg SKU):** $99.99 USD standard list ($10.00/labeled mg; $89.99 USD / $9.00/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** Epithalon (Ala-Glu-Asp-Gly) is a synthetic pineal tetrapeptide demonstrated by Khavinson et al. to induce telomerase activity in human somatic cells and restore nocturnal pineal melatonin secretion. Reconstituting a 10 mg vial with 2.0 mL BAC water yields 5.0 mg/mL (1.0 mg = 20 Units on U-100). - **Titration & Dosing Schedule (10mg + 2mL BAC):** - Days 1–10 (Low-Dose Pulse): 1 mg (1000 mcg) -> 20 Units on U-100 (0.200 mL) | 1.0 mg (20 units at 5 mg/mL) once daily for 10–20 consecutive days (10 doses/vial) - Days 1–10 (Standard Khavinson Cycle): 2 mg (2000 mcg) -> 40 Units on U-100 (0.400 mL) | 2.0 mg (40 units at 5 mg/mL) once daily for 10 days repeated biannually - Days 1–10 (Intensive 5mg Protocol): 5 mg (5000 mcg) -> 100 Units on U-100 (1.000 mL) | 5.0 mg (100 units / 1.0 mL at 5 mg/mL) once daily for 10 days - **Primary Literature Citations:** - Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells (Khavinson et al.) — Bulletin of Experimental Biology and Medicine (2003) · PMID: 12937682 (https://pubmed.ncbi.nlm.nih.gov/12937682/) - Effect of Epitalon on Biomarkers of Aging, Life Span and Spontaneous Tumor Incidence (Anisimov et al.) — Biogerontology (2003) · PMID: 14501183 (https://pubmed.ncbi.nlm.nih.gov/14501183/) --- ## KPV (Lys-Pro-Val C-Terminal α-MSH Tripeptide) - **Canonical Calculator URL:** https://peplab.wiki/compounds/kpv - **Supported Vial Presets:** 10mg (default) - **Category:** Regenerative & Blend (PepT1-Transported Anti-Inflammatory Tripeptide (α-MSH 11-13)) - **CAS Registry Number:** 67727-97-3 - **Molecular Weight:** 342.43 g/mol (C16H30N4O4 free base) - **Sequence / Structure:** 3 amino acids (H-Lys-Pro-Val-OH · C16H30N4O4) - **Chemical Form & Counter-Ion Basis:** Free-base formula C16H30N4O4 (MW 342.43 g/mol; monoisotopic [M+H]+ = 343.23 m/z, verified by LC-MS at 343.300 m/z on Freedom Diagnostics Lot #261102 and Kovera Labs Lot #2026-KV312, CAS 67727-97-3). Lyophilized research vials are commonly isolated as an acetate or trifluoroacetate (TFA) salt; quantitative HPLC net peptide content (10.78 mg net KPV on Kovera Lot #2026-KV312) measures active peptide separately from counter-ion and moisture weight. - **Pharmacokinetic Evidence Status:** Human subcutaneous pharmacokinetic parameters insufficiently established in published literature (multi-day accumulation curve and clearance modeling omitted) — Human subcutaneous pharmacokinetic parameters (terminal half-life and multi-day systemic accumulation) are insufficiently established for KPV in peer-reviewed human literature. Published KPV studies (Dalmasso et al., Gastroenterology 2008, PMID: 18061177; Kannengiesser et al., Inflamm Bowel Dis 2008, PMID: 18092346) evaluate intracellular PepT1 transporter uptake and NF-κB / MAPK signaling in human intestinal epithelial cells and murine colitis models. Multi-day pharmacokinetic superposition modeling is therefore omitted. - **Hypothetical Reconstitution & Aliquot Arithmetic (10mg Vial + 2mL BAC Water):** Concentration = 5 mg/mL (50 mcg/unit). A hypothetical 0.5 mg aliquot equals 0.1 mL = **10 Units** on a U-100 syringe (20 aliquots/vial). - **Supplier $/mg Basis:** $5.58/labeled mg documented (Simms Research, 10mg SKU = $62.00 USD list, $55.80 USD w/ PEPLAB10, checked 2026-11-04; COA: RP-HPLC (C18, DAD @ 214 nm; 3-vial avg 99.531% purity, 10.78 mg net content: 10.34/11.12/10.87 mg) + LC-MS Identity (KPV) + Endotoxin Pass (<=0.5 EU/mL) + Sterility (No Growth) + Heavy Metals Negative) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (10mg SKU):** $62.00 USD standard list ($6.20/labeled mg; $55.80 USD / $5.58/mg 1st order w/ PEPLAB10) | COA Status: dual_metric_pdf_linked (Kovera Labs Lot #2026-KV312, tested 2026-07-16, RP-HPLC purity 99.531%, net mass 10.78 mg/vial) | COA PDF: https://simmsresearch.com/wp-content/uploads/2026/07/coa-kpv-10mg-lot-2026-kv312-kovera-v2.pdf - **True Peptides (10mg SKU):** $50.00 USD standard list ($5.00/labeled mg) | COA Status: purity_only_pdf_linked (Freedom Diagnostics Lot #261102, tested 2026-11-03, RP-HPLC purity 99.98%, net mass not reported on certificate) | COA PDF: https://cdn.true-peptides.com/coa/261102.pdf - **Bergdorf Bioscience (10mg SKU):** $79.99 USD standard list ($8.00/labeled mg; $71.99 USD / $7.20/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** KPV (Lys-Pro-Val, C16H30N4O4, CAS 67727-97-3) is the C-terminal tripeptide fragment (amino acids 11–13) of alpha-melanocyte-stimulating hormone (α-MSH) investigated for PepT1-mediated intracellular inhibition of NF-κB and MAPK inflammatory signaling without pigmentary MC1R activation. Reconstituting a 10 mg vial with 2.0 mL bacteriostatic water yields a 5.0 mg/mL concentration (50 mcg/unit on a U-100 syringe; a hypothetical 0.50 mg aliquot equals 10 Units). - **Dosing Evidence Boundary:** Hypothetical volumetric aliquot arithmetic only (0.20 mg, 0.25 mg, 0.50 mg, and 1.00 mg mass-to-volume conversions for a 10 mg vial reconstituted with 2.0 mL bacteriostatic water = 5.0 mg/mL). No FDA-approved or standardized human clinical dosing regimen exists for KPV. - **Hypothetical Volumetric Aliquot Conversions (Non-Clinical Arithmetic Only) (10mg + 2mL BAC):** - 0.20 mg Aliquot (200 mcg): 0.2 mg (200 mcg) -> 4 Units on U-100 (0.040 mL) | 0.20 mg ÷ 5.0 mg/mL = 0.04 mL = 4 units on U-100 (50 aliquots per 10mg vial; hypothetical dilution arithmetic only) - 0.25 mg Aliquot (250 mcg): 0.25 mg (250 mcg) -> 5 Units on U-100 (0.050 mL) | 0.25 mg ÷ 5.0 mg/mL = 0.05 mL = 5 units on U-100 (40 aliquots per 10mg vial; hypothetical dilution arithmetic only) - 0.50 mg Aliquot (500 mcg): 0.5 mg (500 mcg) -> 10 Units on U-100 (0.100 mL) | 0.50 mg ÷ 5.0 mg/mL = 0.10 mL = 10 units on U-100 (20 aliquots per 10mg vial; hypothetical dilution arithmetic only) - 1.00 mg Aliquot (1,000 mcg): 1 mg (1000 mcg) -> 20 Units on U-100 (0.200 mL) | 1.00 mg ÷ 5.0 mg/mL = 0.20 mL = 20 units on U-100 (10 aliquots per 10mg vial; hypothetical dilution arithmetic only) - **Primary Literature Citations:** - PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation in Human Epithelial Cells and Murine Colitis (Dalmasso et al.) — Gastroenterology (2008) · PMID: 18061177 (https://pubmed.ncbi.nlm.nih.gov/18061177/) - Melanocortin-Derived Tripeptide KPV Has Anti-Inflammatory Potential in Murine Models of Inflammatory Bowel Disease (Kannengiesser et al.) — Inflammatory Bowel Diseases (2008) · PMID: 18092346 (https://pubmed.ncbi.nlm.nih.gov/18092346/) - α-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Anti-Inflammatory Signaling & Receptor Selectivity (Brzoska et al.) — Endocrine Reviews (2008) · PMID: 18612139 (https://pubmed.ncbi.nlm.nih.gov/18612139/) --- ## DSIP (Delta Sleep-Inducing Nonapeptide) - **Canonical Calculator URL:** https://peplab.wiki/compounds/dsip - **Supported Vial Presets:** 10mg (default) - **Category:** Longevity & Neuro (Neuroendocrine & Slow-Wave Sleep Nonapeptide) - **CAS Registry Number:** 62568-57-4 - **Molecular Weight:** 848.81 g/mol (C35H48N10O15 free base) - **Sequence / Structure:** 9 amino acids (H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH · C35H48N10O15) - **Chemical Form & Counter-Ion Basis:** Free-base nonapeptide formula C35H48N10O15 (MW 848.81 g/mol; monoisotopic [M+H]+ = 849.34 m/z, verified by LC-MS at 849.300 m/z on Freedom Diagnostics Lot #261101 and Kovera Labs Lot #2026-DP312, CAS 62568-57-4). Lyophilized research vials are commonly supplied as an acetate salt; quantitative HPLC net peptide content (10.82 mg net DSIP on Kovera Lot #2026-DP312) reports active peptide mass. - **Pharmacokinetic Evidence Status:** Human subcutaneous pharmacokinetic parameters insufficiently established in published literature (multi-day accumulation curve and clearance modeling omitted) — Human subcutaneous pharmacokinetic parameters (terminal half-life and multi-day accumulation profile) are insufficiently established for DSIP in published literature. Analytical and enzymatic degradation reviews (Graf & Kastin, Neurosci Biobehav Rev 1984, PMID: 6392938) and human sleep-architecture studies using intravenous infusions (Bes et al., Neuropsychobiology 1992, PMID: 1299794) do not define a validated human subcutaneous terminal half-life. Multi-day pharmacokinetic superposition modeling is therefore omitted. - **Hypothetical Reconstitution & Aliquot Arithmetic (10mg Vial + 2mL BAC Water):** Concentration = 5 mg/mL (50 mcg/unit). A hypothetical 0.25 mg aliquot equals 0.05 mL = **5 Units** on a U-100 syringe (40 aliquots/vial). - **Supplier $/mg Basis:** $5.50/labeled mg documented (True Peptides, 10mg SKU = $55.00 USD list, checked 2026-11-04; COA: HPLC-UV Purity (99.60%) + LC-MS Identity Confirmed (DSIP; [M+H]+ = 849.300 m/z, [M+H+K]2+ = 444.200 m/z; quantitative mg/vial fill weight not reported on certificate)) | Verifier: https://true-peptides.com/coas?ref=peplab - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **True Peptides (10mg SKU):** $55.00 USD standard list ($5.50/labeled mg) | COA Status: purity_only_pdf_linked (Freedom Diagnostics Lot #261101, tested 2026-11-03, RP-HPLC purity 99.6%, net mass not reported on certificate) | COA PDF: https://cdn.true-peptides.com/coa/261101.pdf - **Bergdorf Bioscience (10mg SKU):** $69.99 USD standard list ($7.00/labeled mg; $62.99 USD / $6.30/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Simms Research (10mg SKU):** $71.00 USD standard list ($7.10/labeled mg; $63.90 USD / $6.39/mg 1st order w/ PEPLAB10) | COA Status: dual_metric_pdf_linked (Kovera Labs Lot #2026-DP312, tested 2026-07-16, RP-HPLC purity 99.775%, net mass 10.82 mg/vial) | COA PDF: https://simmsresearch.com/wp-content/uploads/2026/07/coa-dsip-10mg-lot-2026-dp312-kovera-v2.pdf - **Clinical / Experimental Summary:** DSIP (Delta Sleep-Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, C35H48N10O15, CAS 62568-57-4) is an amphiphilic nonapeptide originally isolated from cerebral venous blood by Schoenenberger et al. (1977) and studied in neuroendocrine and slow-wave sleep research. Reconstituting a 10 mg vial with 2.0 mL bacteriostatic water yields a 5.0 mg/mL concentration (50 mcg/unit on a U-100 syringe; a hypothetical 0.25 mg aliquot equals 5 Units). - **Dosing Evidence Boundary:** Hypothetical volumetric aliquot arithmetic only (0.10 mg, 0.25 mg, 0.50 mg, and 1.00 mg mass-to-volume conversions for a 10 mg vial reconstituted with 2.0 mL bacteriostatic water = 5.0 mg/mL). No standardized human subcutaneous dosing regimen is established for DSIP. - **Hypothetical Volumetric Aliquot Conversions (Non-Clinical Arithmetic Only) (10mg + 2mL BAC):** - 0.10 mg Aliquot (100 mcg): 0.1 mg (100 mcg) -> 2 Units on U-100 (0.020 mL) | 0.10 mg ÷ 5.0 mg/mL = 0.02 mL = 2 units on U-100 (100 aliquots per 10mg vial; hypothetical dilution arithmetic only) - 0.25 mg Aliquot (250 mcg): 0.25 mg (250 mcg) -> 5 Units on U-100 (0.050 mL) | 0.25 mg ÷ 5.0 mg/mL = 0.05 mL = 5 units on U-100 (40 aliquots per 10mg vial; hypothetical dilution arithmetic only) - 0.50 mg Aliquot (500 mcg): 0.5 mg (500 mcg) -> 10 Units on U-100 (0.100 mL) | 0.50 mg ÷ 5.0 mg/mL = 0.10 mL = 10 units on U-100 (20 aliquots per 10mg vial; hypothetical dilution arithmetic only) - 1.00 mg Aliquot (1,000 mcg): 1 mg (1000 mcg) -> 20 Units on U-100 (0.200 mL) | 1.00 mg ÷ 5.0 mg/mL = 0.20 mL = 20 units on U-100 (10 aliquots per 10mg vial; hypothetical dilution arithmetic only) - **Primary Literature Citations:** - Characterization of a Delta-Electroencephalogram (-Sleep)-Inducing Peptide (Schoenenberger et al.) — Proceedings of the National Academy of Sciences (1977) · PMID: 269431 (https://pubmed.ncbi.nlm.nih.gov/269431/) - Delta-Sleep-Inducing Peptide (DSIP): A Review of Analytical, Enzymatic Degradation & Neuroendocrine Studies (Graf & Kastin) — Neuroscience & Biobehavioral Reviews (1984) · PMID: 6392938 (https://pubmed.ncbi.nlm.nih.gov/6392938/) - Effects of Delta Sleep-Inducing Peptide on Sleep of Chronic Insomniac Patients: A Double-Blind Study (Bes et al.) — Neuropsychobiology (1992) · PMID: 1299794 (https://pubmed.ncbi.nlm.nih.gov/1299794/) --- ## Melanotan II (MT-2 Cyclic Melanocortin Agonist) - **Canonical Calculator URL:** https://peplab.wiki/compounds/melanotan-2 - **Supported Vial Presets:** 10mg (default) - **Category:** Longevity & Neuro (Non-Selective Cyclic Melanocortin (MC1R/MC3R/MC4R/MC5R) Agonist) - **CAS Registry Number:** 121062-08-6 - **Molecular Weight:** 1024.18 g/mol (C50H69N15O9 free base) - **Sequence / Structure:** 7 amino acids cyclic lactam (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 · C50H69N15O9) - **Chemical Form & Counter-Ion Basis:** Free-base cyclic lactam formula C50H69N15O9 (MW 1024.18 g/mol, CAS 121062-08-6, verified on Kovera Labs Lot #2026-M2389 and Optiq Health Labs Lot #260908). Supplied as a lyophilized powder (commonly acetate salt); Kovera Labs Lot #2026-M2389 reports 99.679% RP-HPLC purity and 10.82 mg average net content across 3 tested vials. - **Pharmacokinetic Evidence Status:** Human subcutaneous pharmacokinetic parameters insufficiently established in published literature (multi-day accumulation curve and clearance modeling omitted) — Human subcutaneous pharmacokinetic parameters (terminal half-life and multi-day accumulation) are insufficiently established in the cited human clinical studies: Dorr et al. (Life Sciences 1996, PMID: 8637402) and Wessells et al. (Journal of Urology 1998, PMID: 9679884) evaluated pilot subcutaneous pharmacodynamics and tolerability without establishing a validated human subcutaneous terminal half-life, while formal pharmacokinetic disposition modeling by Ugwu et al. (Biopharmaceutics & Drug Disposition 1994, PMID: 7981427) was conducted in rats following intravenous administration. Multi-day human pharmacokinetic superposition modeling and clearance conclusions are therefore omitted. - **Hypothetical Reconstitution & Aliquot Arithmetic (10mg Vial + 2mL BAC Water):** Concentration = 5 mg/mL (50 mcg/unit). A hypothetical 0.25 mg aliquot equals 0.05 mL = **5 Units** on a U-100 syringe (40 aliquots/vial). - **Supplier $/mg Basis:** $4.95/labeled mg documented (Simms Research, 10mg SKU = $55.00 USD list, $49.50 USD w/ PEPLAB10, checked 2026-11-04; COA: RP-HPLC (C18, DAD @ 214 nm; 3-vial avg 99.679% purity, 10.82 mg net content: 10.12/11.43/10.92 mg) + LC-MS Identity (Melanotan-2) + Endotoxin Pass (<=0.5 EU/mL) + Sterility (No Growth) + Heavy Metals Negative) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (10mg SKU):** $55.00 USD standard list ($5.50/labeled mg; $49.50 USD / $4.95/mg 1st order w/ PEPLAB10) | COA Status: dual_metric_pdf_linked (Kovera Labs Lot #2026-M2389, tested 2026-07-16, RP-HPLC purity 99.679%, net mass 10.82 mg/vial) | COA PDF: https://simmsresearch.com/wp-content/uploads/2026/07/coa-melanotan-ii-10mg-lot-2026-m2389-kovera-v2.pdf - **True Peptides (10mg SKU):** $36.00 USD standard list ($3.60/labeled mg) | COA Status: purity_only_pdf_linked (Optiq Health Labs, LLC Lot #260908, tested 2026-09-22, RP-HPLC purity 99.5%, net mass not reported on certificate) | COA PDF: https://cdn.true-peptides.com/coa/260908.pdf - **Bergdorf Bioscience (10mg SKU):** $71.99 USD standard list ($7.20/labeled mg; $64.79 USD / $6.48/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** Melanotan II (MT-2, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, C50H69N15O9, CAS 121062-08-6) is a synthetic cyclic lactam heptapeptide analogue of α-MSH evaluated as a non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R in early clinical and preclinical investigations (Dorr et al., 1996; Wessells et al., 1998; Ugwu et al., 1994). Reconstituting a 10 mg vial with 2.0 mL bacteriostatic water yields a 5.0 mg/mL concentration (50 mcg/unit on a U-100 syringe; a hypothetical 0.25 mg aliquot equals 5 Units). - **Dosing Evidence Boundary:** Hypothetical volumetric aliquot arithmetic only (0.10 mg, 0.25 mg, 0.50 mg, and 1.00 mg mass-to-volume conversions for a 10 mg vial reconstituted with 2.0 mL bacteriostatic water = 5.0 mg/mL). Fixed-milligram aliquots are not equivalent to weight-adjusted (mg/kg) experimental regimens. Melanotan II is an unapproved research reagent with no approved human dosing schedule. - **Hypothetical Volumetric Aliquot Conversions (Non-Clinical Arithmetic Only) (10mg + 2mL BAC):** - 0.10 mg Aliquot (100 mcg): 0.1 mg (100 mcg) -> 2 Units on U-100 (0.020 mL) | 0.10 mg ÷ 5.0 mg/mL = 0.02 mL = 2 units on U-100 (100 aliquots per 10mg vial; hypothetical dilution arithmetic only) - 0.25 mg Aliquot (250 mcg): 0.25 mg (250 mcg) -> 5 Units on U-100 (0.050 mL) | 0.25 mg ÷ 5.0 mg/mL = 0.05 mL = 5 units on U-100 (40 aliquots per 10mg vial; hypothetical dilution arithmetic only) - 0.50 mg Aliquot (500 mcg): 0.5 mg (500 mcg) -> 10 Units on U-100 (0.100 mL) | 0.50 mg ÷ 5.0 mg/mL = 0.10 mL = 10 units on U-100 (20 aliquots per 10mg vial; hypothetical dilution arithmetic only) - 1.00 mg Aliquot (1,000 mcg): 1 mg (1000 mcg) -> 20 Units on U-100 (0.200 mL) | 1.00 mg ÷ 5.0 mg/mL = 0.20 mL = 20 units on U-100 (10 aliquots per 10mg vial; hypothetical dilution arithmetic only) - **Primary Literature Citations:** - Evaluation of Melanotan-II, a Superpotent Cyclic Melanotropic Peptide in a Pilot Phase-I Clinical Study (Dorr et al.) — Life Sciences (1996) · PMID: 8637402 (https://pubmed.ncbi.nlm.nih.gov/8637402/) - Synthetic Melanotropic Peptide Initiates Erections in Men with Psychogenic Erectile Dysfunction: Double-Blind Crossover Study (Wessells et al.) — Journal of Urology (1998) · PMID: 9679884 (https://pubmed.ncbi.nlm.nih.gov/9679884/) - Disposition of Melanotan-II Following Intravenous Administration in Rats (Ugwu et al.) — Biopharmaceutics & Drug Disposition (1994) · PMID: 7981427 (https://pubmed.ncbi.nlm.nih.gov/7981427/) --- ## PT-141 (Bremelanotide Cyclic Melanocortin Agonist) - **Canonical Calculator URL:** https://peplab.wiki/compounds/pt-141 - **Supported Vial Presets:** 10mg (default) - **Category:** Longevity & Neuro (Cyclic Heptapeptide Melanocortin Agonist (MC1R / MC4R)) - **CAS Registry Number:** 189691-06-3 - **Molecular Weight:** 1025.16 g/mol (C50H68N14O10 free base) - **Sequence / Structure:** 7 amino acids cyclic lactam (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH · C50H68N14O10) - **Chemical Form & Counter-Ion Basis:** Free-base cyclic heptapeptide lactam formula C50H68N14O10 (MW 1025.16 g/mol, CAS 189691-06-3), carrying a C-terminal carboxylic acid (-OH) in contrast to Melanotan II’s C-terminal carboxamide (-NH2). FDA-approved Vyleesi (NDA 210557) is formulated as bremelanotide acetate in a single-dose autoinjector (1.75 mg free-base equivalent in 0.3 mL). Lyophilized research vials are commonly isolated as an acetate salt: True Peptides Optiq Health Labs Lot #260907 (COA UID: 1462.OPT.260918-R1, tested 2026-09-22) confirms LC-MS identity and 99.2% RP-HPLC purity for a supplier-labeled quantity (10 mg), with quantitative net peptide content not reported; Simms Research (10 mg SKU) has no public batch COA located as of 2026-11-04. - **Pharmacokinetic Evidence Status:** Documented (FDA Label t½ 2.7h) (multi-day accumulation simulator omitted: Omitted (Intermittent PRN Drug)) — Human subcutaneous pharmacokinetics are documented in the FDA Vyleesi (bremelanotide injection, NDA 210557, §12.3) prescribing information: following a 1.75 mg subcutaneous dose, median Tmax is ~1.0 hour (range 0.5–1.0 h), absolute subcutaneous bioavailability is ~100%, mean plasma protein binding is 21%, and mean terminal half-life (t½) is approximately 2.7 hours (0.1125 days). Multi-day accumulation simulation is intentionally omitted because bremelanotide is an intermittent as-needed (PRN) agent (maximum 1 dose per 24 hours and ≤8 doses per month due to transient blood pressure elevation and focal hyperpigmentation risk) and the approved autoinjector drug label does not establish bioequivalence for unapproved lyophilized research vials. - **Hypothetical Reconstitution & Aliquot Arithmetic (10mg Vial + 2mL BAC Water):** Concentration = 5 mg/mL (50 mcg/unit). A hypothetical 1.75 mg aliquot equals 0.35 mL = **35 Units** on a U-100 syringe (5.7 aliquots/vial). - **Supplier $/mg Basis:** $4.30/labeled mg documented (True Peptides, 10mg SKU = $43.00 USD list, checked 2026-11-04; COA: RP-HPLC Purity (99.2%, spec >=98.0%) + LC-MS Identity Confirmation (PT-141 Bremelanotide; supplier-labeled quantity (10 mg); quantitative content not reported on certificate)) | Verifier: https://true-peptides.com/coas?ref=peplab - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **True Peptides (10mg SKU):** $43.00 USD standard list ($4.30/labeled mg) | COA Status: purity_only_pdf_linked (Optiq Health Labs, LLC Lot #260907, tested 2026-09-22, RP-HPLC purity 99.2%, net mass not reported on certificate) | COA PDF: https://cdn.true-peptides.com/coa/260907.pdf - **Bergdorf Bioscience (10mg SKU):** $69.99 USD standard list ($7.00/labeled mg; $62.99 USD / $6.30/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Simms Research (10mg SKU):** $64.00 USD standard list ($6.40/labeled mg; $57.60 USD / $5.76/mg 1st order w/ PEPLAB10) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Clinical / Experimental Summary:** PT-141 (Bremelanotide, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, C50H68N14O10, CAS 189691-06-3) is a cyclic heptapeptide melanocortin receptor agonist (MC1R/MC4R) whose C-terminal carboxylic acid distinguishes it chemically from Melanotan II. FDA prescribing information for Vyleesi (NDA 210557) documents a ~2.7-hour subcutaneous terminal half-life and ~100% bioavailability for a 1.75 mg intermittent PRN dose (max 1 dose/24h, max 8 doses/month). Reconstituting a 10 mg research vial with 2.0 mL bacteriostatic water yields 5.0 mg/mL (50 mcg/unit on a U-100 syringe; a 1.75 mg aliquot equals 35 Units). - **Dosing Evidence Boundary:** Reference dilution arithmetic only (0.25 mg, 0.50 mg, 1.00 mg, and 1.75 mg mass-to-volume conversions for a 10 mg vial reconstituted with 2.0 mL bacteriostatic water = 5.0 mg/mL; 1.75 mg equals 0.35 mL = 35 Units on a U-100 syringe). In FDA label NDA 210557 (Vyleesi), the approved adult dose for premenopausal HSDD is 1.75 mg subcutaneously as needed ≥45 minutes before anticipated activity, with strict labeling limits of no more than one dose within 24 hours and no more than 8 doses per month. Unapproved research vials are not bioequivalent to Vyleesi. - **Hypothetical Volumetric Aliquot Conversions (Non-Clinical Arithmetic Only) (10mg + 2mL BAC):** - 0.25 mg Aliquot (250 mcg): 0.25 mg (250 mcg) -> 5 Units on U-100 (0.050 mL) | 0.25 mg ÷ 5.0 mg/mL = 0.05 mL = 5 units on U-100 (40 aliquots per 10mg vial; reference dilution arithmetic only) - 0.50 mg Aliquot (500 mcg): 0.5 mg (500 mcg) -> 10 Units on U-100 (0.100 mL) | 0.50 mg ÷ 5.0 mg/mL = 0.10 mL = 10 units on U-100 (20 aliquots per 10mg vial; reference dilution arithmetic only) - 1.00 mg Aliquot (1,000 mcg): 1 mg (1000 mcg) -> 20 Units on U-100 (0.200 mL) | 1.00 mg ÷ 5.0 mg/mL = 0.20 mL = 20 units on U-100 (10 aliquots per 10mg vial; reference dilution arithmetic only) - 1.75 mg Aliquot (1,750 mcg): 1.75 mg (1750 mcg) -> 35 Units on U-100 (0.350 mL) | 1.75 mg ÷ 5.0 mg/mL = 0.35 mL = 35 units on U-100 (~5.7 aliquots per 10mg vial; NDA 210557 PRN label reference mass: max 1 dose/24h, ≤8/month) - **Primary Literature Citations:** - FDA Vyleesi (Bremelanotide Injection) Prescribing Information — NDA 210557 (§11 Description & §12.3 Pharmacokinetics) — U.S. Food and Drug Administration (2020) · NDA 210557 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf) - Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials — RECONNECT (Kingsberg et al.) — Obstetrics & Gynecology (2019) · PMID: 31599840 (https://pubmed.ncbi.nlm.nih.gov/31599840/) --- ## SS-31 (Elamipretide / MTP-131 Cardiolipin-Targeting Tetrapeptide) - **Canonical Calculator URL:** https://peplab.wiki/compounds/ss-31 - **Supported Vial Presets:** 10mg (default), 50mg - **Category:** Longevity & Neuro (Inner Mitochondrial Membrane Cardiolipin-Stabilizing Tetrapeptide) - **CAS Registry Number:** 736992-21-5 - **Molecular Weight:** 639.79 g/mol (C32H49N9O5 free base) - **Sequence / Structure:** 4 amino acids (H-D-Arg-Dmt-Lys-Phe-NH2 · C32H49N9O5) - **Chemical Form & Counter-Ion Basis:** Free-base aromatic-cationic tetrapeptide formula C32H49N9O5 (D-Arg-2',6'-dimethyl-L-tyrosine-L-Lys-L-Phe-NH2, MW 639.79 g/mol, CAS 736992-21-5). Clinical formulations have been studied as hydrochloride or acetate salts; in 2025, elamipretide received FDA accelerated approval as Forzinity (NDA 215244) for Barth syndrome. True Peptides (10 mg SKU TP-SS10) publishes Optiq Health Labs Lot #261002 (COA UID: 1704.OPT.261012-R1, tested 2026-10-14) reporting 99.9% RP-HPLC purity and LC-MS identity confirmation without quantitative mg/vial net content; its 50 mg SKU (TP-SS50) has no separate 50 mg batch COA located. Simms Research (10 mg SKU) has no public batch COA located as of 2026-11-04. - **Pharmacokinetic Evidence Status:** Documented (FDA Label NDA 215244) (multi-day accumulation simulator omitted: Omitted (Renal-Dependent PK)) — Human subcutaneous pharmacokinetics and renal-impairment exposure relationships for elamipretide (SS-31 / MTP-131) are documented in the 2025 FDA Forzinity prescribing information (NDA 215244, §12.3) and subcutaneous clinical trials (TAZPOWER, Reid Thompson et al., Genet Med 2021, PMID: 33077895; MMPOWER-2, Karaa et al., J Cachexia Sarcopenia Muscle 2020, PMID: 32096613). Multi-day pharmacokinetic superposition graphing is intentionally omitted here because the simplified 1-compartment web model is not validated for elamipretide’s renal-function-dependent disposition (and M1/M2 metabolite clearance) or for unapproved lyophilized research vials. - **Hypothetical Reconstitution & Aliquot Arithmetic (10mg Vial + 2mL BAC Water):** Concentration = 5 mg/mL (50 mcg/unit). A hypothetical 2 mg aliquot equals 0.4 mL = **40 Units** on a U-100 syringe (5 aliquots/vial). - **Supplier $/mg Basis:** $6.00/labeled mg documented (True Peptides, 10mg SKU = $60.00 USD list, checked 2026-11-04; COA: RP-HPLC Purity (99.9%, spec >=95%) + LC-MS Identity Confirmation (SS-31; quantitative mg/vial fill weight not reported on certificate)) | Verifier: https://true-peptides.com/coas?ref=peplab - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **True Peptides (10mg SKU):** $60.00 USD standard list ($6.00/labeled mg) | COA Status: purity_only_pdf_linked (Optiq Health Labs, LLC Lot #261002, tested 2026-10-14, RP-HPLC purity 99.9%, net mass not reported on certificate) | COA PDF: https://cdn.true-peptides.com/coa/261002.pdf - **Bergdorf Bioscience (10mg SKU):** $94.99 USD standard list ($9.50/labeled mg; $85.49 USD / $8.55/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** SS-31 (Elamipretide / MTP-131, D-Arg-Dmt-Lys-Phe-NH2, C32H49N9O5, CAS 736992-21-5) is a mitochondria-penetrating aromatic-cationic tetrapeptide that binds selectively to cardiolipin on the inner mitochondrial membrane to stabilize cristae curvature and electron transport chain supercomplexes. Elamipretide received FDA accelerated approval in 2025 as Forzinity (NDA 215244) for Barth syndrome. Reconstituting a 10 mg research vial with 2.0 mL bacteriostatic water yields 5.0 mg/mL (50 mcg/unit on a U-100 syringe; a 2.0 mg aliquot equals 40 Units). - **Dosing Evidence Boundary:** Reference dilution arithmetic only (1.0 mg, 2.0 mg, 4.0 mg, and 5.0 mg mass-to-volume conversions for a 10 mg vial reconstituted with 2.0 mL bacteriostatic water = 5.0 mg/mL; at 40 mg daily in clinical trials such as TAZPOWER and MMPOWER-2, high-concentration clinical formulations were used). Unapproved research vials are not bioequivalent to FDA-approved Forzinity (NDA 215244). - **Hypothetical Volumetric Aliquot Conversions (Non-Clinical Arithmetic Only) (10mg + 2mL BAC):** - 1.0 mg Aliquot (1,000 mcg): 1 mg (1000 mcg) -> 20 Units on U-100 (0.200 mL) | 1.0 mg ÷ 5.0 mg/mL = 0.20 mL = 20 units on U-100 (10 aliquots per 10mg vial; reference dilution arithmetic only) - 2.0 mg Aliquot (2,000 mcg): 2 mg (2000 mcg) -> 40 Units on U-100 (0.400 mL) | 2.0 mg ÷ 5.0 mg/mL = 0.40 mL = 40 units on U-100 (5 aliquots per 10mg vial; reference dilution arithmetic only) - 4.0 mg Aliquot (4,000 mcg): 4 mg (4000 mcg) -> 80 Units on U-100 (0.800 mL) | 4.0 mg ÷ 5.0 mg/mL = 0.80 mL = 80 units on U-100 (2.5 aliquots per 10mg vial; reference dilution arithmetic only) - 5.0 mg Aliquot (5,000 mcg): 5 mg (5000 mcg) -> 100 Units on U-100 (1.000 mL) | 5.0 mg ÷ 5.0 mg/mL = 1.00 mL = 100 units on U-100 (2 aliquots per 10mg vial; reference dilution arithmetic only) - **Primary Literature Citations:** - FDA Forzinity (Elamipretide Injection) Prescribing Information — NDA 215244 (§11 Description & §12.3 Pharmacokinetics) — U.S. Food and Drug Administration (2025) · NDA 215244 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf) - A Phase 2/3 Randomized Clinical Trial Followed by an Open-Label Extension to Evaluate the Effectiveness of Elamipretide in Barth Syndrome — TAZPOWER (Reid Thompson et al.) — Genetics in Medicine (2021) · PMID: 33077895 (https://pubmed.ncbi.nlm.nih.gov/33077895/) - A Randomized Crossover Trial of Elamipretide in Primary Mitochondrial Myopathy — MMPOWER-2 (Karaa et al.) — Journal of Cachexia, Sarcopenia and Muscle (2020) · PMID: 32096613 (https://pmc.ncbi.nlm.nih.gov/articles/PMC7432581/) --- ## Kisspeptin-10 (Metastin 45–54 Hypothalamic GnRH Secretagogue) - **Canonical Calculator URL:** https://peplab.wiki/compounds/kisspeptin-10 - **Supported Vial Presets:** 10mg (default) - **Category:** GH Secretagogue (KISS1R (GPR54) Hypothalamic GnRH / LH Pulse Secretagogue) - **CAS Registry Number:** 374675-21-5 - **Molecular Weight:** 1302.44 g/mol (C63H83N17O14 free base) - **Sequence / Structure:** 10 amino acids (H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 · C63H83N17O14) - **Chemical Form & Counter-Ion Basis:** Free-base C-terminal amidated decapeptide formula C63H83N17O14 (Kisspeptin-54 [45–54] / Metastin [45–54], MW 1302.44 g/mol, CAS 374675-21-5). Lyophilized research vials are commonly supplied as a trifluoroacetate (TFA) or acetate salt. True Peptides (SKU TP-KS10) publishes Freedom Diagnostics Lot #261103 (Accession #2611022165, tested 2026-11-03) reporting 99.42% HPLC-UV purity and LC-MS identity confirmation ([M+2H]2+ = 651.900 m/z, [M+H]+ = 1302.700 m/z; quantitative mg/vial net content not reported). No public batch COA was located on Simms Research for Kisspeptin-10 as of 2026-11-04. - **Pharmacokinetic Evidence Status:** Documented (IV Infusion t½ ~4m) (multi-day accumulation simulator omitted: Omitted (Ultra-Short IV t½)) — Human plasma decay half-life following cessation of intravenous Kisspeptin-10 infusion is documented at 3.8 ± 0.3 minutes in healthy men and 4.1 ± 0.4 minutes in healthy women (~4 minutes) in Study 5 of Jayasena et al. (J Clin Endocrinol Metab 2011, PMID: 21976724, PMC3232613), while George et al. (J Clin Endocrinol Metab 2011, PMID: 21632807) characterized intravenous bolus and infusion LH pulse stimulation in healthy men. Because an ultra-short (~4-minute) post-IV plasma half-life cannot be extrapolated to a multi-day subcutaneous accumulation model, multi-day pharmacokinetic superposition graphing is omitted. - **Hypothetical Reconstitution & Aliquot Arithmetic (10mg Vial + 2mL BAC Water):** Concentration = 5 mg/mL (50 mcg/unit). A hypothetical 0.2 mg aliquot equals 0.04 mL = **4 Units** on a U-100 syringe (50 aliquots/vial). - **Supplier $/mg Basis:** $5.50/labeled mg documented (True Peptides, 10mg SKU = $55.00 USD list, checked 2026-11-04; COA: HPLC-UV Purity (99.42%) + LC-MS Identity Confirmed (Kisspeptin; [M+2H]2+ = 651.900 m/z, [M+H]+ = 1302.700 m/z; quantitative mg/vial fill weight not reported on certificate)) | Verifier: https://true-peptides.com/coas?ref=peplab - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **True Peptides (10mg SKU):** $55.00 USD standard list ($5.50/labeled mg) | COA Status: purity_only_pdf_linked (Freedom Diagnostics Lot #261103, tested 2026-11-03, RP-HPLC purity 99.42%, net mass not reported on certificate) | COA PDF: https://cdn.base-frame.com/coa/261103.pdf - **Bergdorf Bioscience (10mg SKU):** $73.90 USD standard list ($7.39/labeled mg; $66.51 USD / $6.65/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Simms Research (10mg SKU):** $74.00 USD standard list ($7.40/labeled mg; $66.60 USD / $6.66/mg 1st order w/ PEPLAB10) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Clinical / Experimental Summary:** Kisspeptin-10 (Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2, C63H83N17O14, CAS 374675-21-5) is the conserved C-terminal decapeptide sequence (residues 45–54) of Kisspeptin-54 that acts as an endogenous ligand at hypothalamic KISS1R (GPR54) receptors to stimulate pulsatile GnRH, LH, and FSH secretion (George et al., 2011; Jayasena et al., 2011). Reconstituting a 10 mg vial with 2.0 mL bacteriostatic water yields 5.0 mg/mL (50 mcg/unit on a U-100 syringe; a hypothetical 0.20 mg aliquot equals 4 Units). - **Dosing Evidence Boundary:** Hypothetical volumetric aliquot arithmetic only (0.10 mg, 0.20 mg, 0.50 mg, and 1.00 mg mass-to-volume conversions for a 10 mg vial reconstituted with 2.0 mL bacteriostatic water = 5.0 mg/mL). Clinical endocrine studies (George et al., 2011; Jayasena et al., 2011) administered weight-adjusted (nmol/kg or mcg/kg) boluses and infusions rather than fixed-milligram chronic subcutaneous regimens. - **Hypothetical Volumetric Aliquot Conversions (Non-Clinical Arithmetic Only) (10mg + 2mL BAC):** - 0.10 mg Aliquot (100 mcg): 0.1 mg (100 mcg) -> 2 Units on U-100 (0.020 mL) | 0.10 mg ÷ 5.0 mg/mL = 0.02 mL = 2 units on U-100 (100 aliquots per 10mg vial; hypothetical dilution arithmetic only) - 0.20 mg Aliquot (200 mcg): 0.2 mg (200 mcg) -> 4 Units on U-100 (0.040 mL) | 0.20 mg ÷ 5.0 mg/mL = 0.04 mL = 4 units on U-100 (50 aliquots per 10mg vial; hypothetical dilution arithmetic only) - 0.50 mg Aliquot (500 mcg): 0.5 mg (500 mcg) -> 10 Units on U-100 (0.100 mL) | 0.50 mg ÷ 5.0 mg/mL = 0.10 mL = 10 units on U-100 (20 aliquots per 10mg vial; hypothetical dilution arithmetic only) - 1.00 mg Aliquot (1,000 mcg): 1 mg (1000 mcg) -> 20 Units on U-100 (0.200 mL) | 1.00 mg ÷ 5.0 mg/mL = 0.20 mL = 20 units on U-100 (10 aliquots per 10mg vial; hypothetical dilution arithmetic only) - **Primary Literature Citations:** - Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in Men (George et al.) — Journal of Clinical Endocrinology & Metabolism (2011) · PMID: 21632807 (https://pubmed.ncbi.nlm.nih.gov/21632807/) - The Effects of Kisspeptin-10 on Reproductive Hormone Release Show Sexual Dimorphism in Humans (Jayasena et al.) — Journal of Clinical Endocrinology & Metabolism (2011) · PMID: 21976724 (https://pmc.ncbi.nlm.nih.gov/articles/PMC3232613/) --- ## Selank (TP-7 Synthetic Tuftsin-Pro-Gly-Pro Heptapeptide) - **Canonical Calculator URL:** https://peplab.wiki/compounds/selank - **Supported Vial Presets:** 10mg (default) - **Category:** Longevity & Neuro (Tuftsin-Derived Anxiolytic & Enkephalinase-Modulating Heptapeptide) - **CAS Registry Number:** 129954-34-3 - **Molecular Weight:** 751.87 g/mol (C33H57N11O9 free base) - **Sequence / Structure:** 7 amino acids (H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH · C33H57N11O9) - **Chemical Form & Counter-Ion Basis:** Free-base heptapeptide formula C33H57N11O9 (Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to endogenous tuftsin Thr-Lys-Pro-Arg extended at the C-terminus by the tripeptide Pro-Gly-Pro, MW 751.87 g/mol, CAS 129954-34-3). Lyophilized research vials are commonly supplied as an acetate salt. Simms Research publishes Kovera Labs Lot #2026-SL286 (Report ID: KVR-2026-827CV1, tested 2026-07-16) reporting 99.749% RP-HPLC purity and 10.54 mg average net content across 3 tested vials (10.21/10.53/10.89 mg). No public batch-specific COA was located on True Peptides (SKU TP-SK10) as of 2026-11-04. - **Pharmacokinetic Evidence Status:** Human subcutaneous pharmacokinetic parameters insufficiently established in published literature (multi-day accumulation curve and clearance modeling omitted) — Human subcutaneous pharmacokinetic parameters (terminal half-life and systemic accumulation) are not established in the cited clinical literature. Published human clinical studies of Selank (Zozulia et al., Zh Nevrol Psikhiatr Im S S Korsakova 2008, PMID: 18454096; Medvedev et al., Zh Nevrol Psikhiatr Im S S Korsakova 2014, PMID: 25176261) evaluated intranasal administration in generalized anxiety disorder and neurasthenia, and Zozulia et al. (2008) investigated plasma Leu-enkephalin half-life and enkephalinase activity rather than establishing a human subcutaneous terminal half-life for Selank. Multi-day subcutaneous pharmacokinetic superposition modeling is therefore omitted. - **Hypothetical Reconstitution & Aliquot Arithmetic (10mg Vial + 2mL BAC Water):** Concentration = 5 mg/mL (50 mcg/unit). A hypothetical 0.25 mg aliquot equals 0.05 mL = **5 Units** on a U-100 syringe (40 aliquots/vial). - **Supplier $/mg Basis:** $4.95/labeled mg documented (Simms Research, 10mg SKU = $55.00 USD list, $49.50 USD w/ PEPLAB10, checked 2026-11-04; COA: RP-HPLC (C18, DAD @ 214 nm; 3-vial avg 99.749% purity, 10.54 mg net content: 10.21/10.53/10.89 mg) + LC-MS Identity (Selank) + Endotoxin Pass (<=0.5 EU/mL) + Sterility (No Growth) + Heavy Metals Negative) | Verifier: https://simmsresearch.com/lab-results/?sr_ref=PEPLAB10 - **Documented Supplier Catalog & Batch COA Comparison (https://peplab.wiki/compare/simms-research-vs-true-peptides):** - **Simms Research (10mg SKU):** $55.00 USD standard list ($5.50/labeled mg; $49.50 USD / $4.95/mg 1st order w/ PEPLAB10) | COA Status: dual_metric_pdf_linked (Kovera Labs Lot #2026-SL286, tested 2026-07-16, RP-HPLC purity 99.749%, net mass 10.54 mg/vial) | COA PDF: https://simmsresearch.com/wp-content/uploads/2026/07/coa-selank-10mg-lot-2026-sl286-kovera-v2.pdf - **True Peptides (10mg SKU):** $45.00 USD standard list ($4.50/labeled mg) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://true-peptides.com/coas?ref=peplab - **Bergdorf Bioscience (10mg SKU):** $56.99 USD standard list ($5.70/labeled mg; $51.29 USD / $5.13/mg 1st order w/ BIO-QTVGWU) | COA Status: missing_public_coa (Lab , no public batch COA PDF linked in snapshot) | COA PDF: https://bergdorfbio.com/en/us/peptides?ref=BIO-QTVGWU - **Clinical / Experimental Summary:** Selank (TP-7, Thr-Lys-Pro-Arg-Pro-Gly-Pro, C33H57N11O9, CAS 129954-34-3) is a synthetic heptapeptide analogue of the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg) stabilized at the C-terminus with a Pro-Gly-Pro tripeptide sequence and studied in Russian clinical trials for GABAergic and enkephalinase-modulating activity (Zozulia et al., 2008; Medvedev et al., 2014). Reconstituting a 10 mg vial with 2.0 mL bacteriostatic water yields 5.0 mg/mL (50 mcg/unit on a U-100 syringe; a hypothetical 0.25 mg aliquot equals 5 Units). - **Dosing Evidence Boundary:** Hypothetical volumetric aliquot arithmetic only (0.25 mg, 0.50 mg, 0.75 mg, and 1.00 mg mass-to-volume conversions for a 10 mg vial reconstituted with 2.0 mL bacteriostatic water = 5.0 mg/mL). Published clinical trials in Russia investigated intranasal drops (0.15% aqueous solution) rather than subcutaneous injection; no FDA-approved or validated human subcutaneous dosing regimen exists for Selank. - **Hypothetical Volumetric Aliquot Conversions (Non-Clinical Arithmetic Only) (10mg + 2mL BAC):** - 0.25 mg Aliquot (250 mcg): 0.25 mg (250 mcg) -> 5 Units on U-100 (0.050 mL) | 0.25 mg ÷ 5.0 mg/mL = 0.05 mL = 5 units on U-100 (40 aliquots per 10mg vial; hypothetical dilution arithmetic only) - 0.50 mg Aliquot (500 mcg): 0.5 mg (500 mcg) -> 10 Units on U-100 (0.100 mL) | 0.50 mg ÷ 5.0 mg/mL = 0.10 mL = 10 units on U-100 (20 aliquots per 10mg vial; hypothetical dilution arithmetic only) - 0.75 mg Aliquot (750 mcg): 0.75 mg (750 mcg) -> 15 Units on U-100 (0.150 mL) | 0.75 mg ÷ 5.0 mg/mL = 0.15 mL = 15 units on U-100 (~13.3 aliquots per 10mg vial; hypothetical dilution arithmetic only) - 1.00 mg Aliquot (1,000 mcg): 1 mg (1000 mcg) -> 20 Units on U-100 (0.200 mL) | 1.00 mg ÷ 5.0 mg/mL = 0.20 mL = 20 units on U-100 (10 aliquots per 10mg vial; hypothetical dilution arithmetic only) - **Primary Literature Citations:** - Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalized Anxiety Disorders and Neurasthenia (Zozulia et al.) — Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (2008) · PMID: 18454096 (https://pubmed.ncbi.nlm.nih.gov/18454096/) - Optimization of the Treatment of Anxiety Disorders with Selank (Medvedev et al.) — Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (2014) · PMID: 25176261 (https://pubmed.ncbi.nlm.nih.gov/25176261/)